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ABSTRACT

Amphotericin B is a drug of choice for severe and/or deep-seated ocular fungal infections
(OFI). An ophthalmic marketed amphotericin B formulation is currently not available; parenteral
marketed preparations (FungizoneTM and AmBisome®) are prescribed (off-label) to treat OFI
(keratitis and endophthalmitis). Current amphotericin B off-label therapy to treat OFI requires
frequent topical administration (every hour) due to the poor permeation and precorneal retention
associated with it. Therefore, a need arises to formulate an ophthalmic preparation with multidose
compatibility, enhanced precorneal retention, and reduced frequency of dosing, whilst,
maintaining ocular tissue concentrations comparable/superior to the marketed preparations.
The Chapter I work focuses on formulating and stabilizing amphotericin B-loaded nanostructured
lipid carriers (AmB-NLC) by PEGylating using optimum PEG molecular weight and optimizing
it for ocular drug delivery. A 4-week stability (physical and chemical), in vitro transcorneal
permeability, in vitro antifungal efficacy and cytotoxicity, and in vivo ocular distribution following
topical administration in rabbits for optimized formulations was evaluated. This is first attempt to
formulate and optimize (design of experiment approach) PEG-NLC-AmB for ocular drug delivery
with: an enhanced drug load, an organic solvent-free process, and using a high-pressure
homogenizer.
The Chapter II focuses on formulation of an optimized and robust amphotericin B ocular
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formulation with prolonged precorneal residence and ocular tissue concentration at par or superior
to the marketed preparations. Additionally, demonstrating stability of amphotericin B formulations
in presence of preservative in comparison to marketed preparation, making it an ideal choice of
formulation for multi-dosing. As mentioned earlier, we optimized PEGylated nanostructured lipid
carriers (PEG-NLC-AmB) for ocular delivery of amphotericin B. The formulations could be
autoclaved with at least one-month stability and in vivo ocular biodistribution was statistically
insignificantly different compared to AmBisome®. To accomplish the aim, strategies such as
mucoadhesion and/or viscosity enhancement were investigated. In this regard, PEG-NLC-AmB
entrapped in ion triggered hydrogels using gellan gum (mucoadhesive) and chitosan
(mucoadhesive and permeation enhancer) coated PEG-NLC-AmB were formulated and
characterized.
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ABBREVIATIONS
NLC Nanostructured Lipid Carriers
AmB Amphotericin B
NLC-AmB Amphotericin B Loaded Nanostructured Lipid Carriers
PEG-NLC-AmB Amphotericin B Loaded PEGylated Nanostructured lipid carriers
SLN Solid Lipid Nanoparticles
Chi-PEG2K-NLC-AmB Chitosan coated Amphotericin B Loaded PEGylated Nanostructured
Lipid Carriers
ADME Absorption Distribution Metabolism Elimination
BAB Blood-Aqueous Barrier
BRB Blood-Retinal Barrier
QbD Quality by Design
CQA Critical quality attributes
CPP Critical process parameters
DOE Design of experiment
PK-PD Pharmacokinetic-Pharmacodynamic
AH Aqueous humor
VH Vitreous humor
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IC Iris-ciliary bodies
RC Retina-choroid
IPBS Isotonic phosphate buffer
ANOVA Analysis of Variance
STEM Scanning transmission electron microscopy
PDI Polydispersity Index
DLS Dynamic Light Scattering
THC-HG Δ
CH Chitosan
RMβCD Randomly methylated β cyclodextrin
EE Entrapment Efficiency
r2 Regression coefficient
Cor Cornea
SC Sclera
ESI Electrospray ionization
MRT Mean residence time
CL Clearance
DL Drug load
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CHAPTER I
INTRODUCTION AND SPECIFIC AIMS
Introduction to ocular drug delivery
Epidemiology of ocular diseases
Ocular drug delivery has remained a challenging task for pharmaceutical scientists. This coupled
with the aging population and manifestation of other age-related diseases, explains why the
National Eye Institute (NEI) has predicted a significant rise in clinical cases involving diseases
affecting the ocular segments, across various age and ethnic groups (3). This review focuses on
the rising use of noninvasive nanotechnology to improve the therapeutic outcomes in diseases
affecting the anterior segment of the eye. The frequently encountered sight-threatening anterior
segment ocular diseases are cataract, glaucoma, keratitis, ocular hypertension, and uveitis (4-7).
According to the NEI and the World Health Organization (WHO), cataract is one of the major
causes of blindness, accounting for 51 % of the blindness worldwide (3, 8-10).
Topical administration, a localized noninvasive technique, is the most preferred route of dosing
for anterior segment ocular diseases. The topical route, however, is associated with low ocular
bioavailability (less than 5% of the administered dose) because of various physiological and
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mechanical barriers (7). Conventional topical ophthalmic formulations include eye drops
(solutions, suspensions) and ointments. Some emulsion formulations are also currently in the
market (Restasis®, Cationorm®). Limited retention on the ocular surface and the need for the drug
candidate to possess ideal physicochemical characteristics, to facilitate efficient penetration
through the complex ocular structures, however, limits the efficiency of these dosage forms (11).
Solutions are rapidly drained from the conjunctival cul de sac allowing very little time for the drug
to partition into the ocular tissues. Moreover, the instilled drop size must be in the range of 25-50
µL which does not allow for the development of a high concentration gradient across the ocular
tissues and demands good solubility characteristics, especially at the pH of the tear fluids.
To improve the efficacy of the topical ophthalmic solutions or suspensions, high viscosity
(thixotropic or shear-thinning) solutions and hydrogels, have been developed to increase retention
on the ocular surface (12). Moreover, in contrast to solutions, suspension formulations are better
retained on the ocular surface because of the deposition of the drug particles in the conjunctival
cul de sac. Suspensions are also the primary choice for compounds with poor aqueous solubility
(in relation to the target dose). Compared to solutions and suspensions, ointments are not
commonly used for conditions affecting the eye because of the oily components that affect vision
for some time following application. In all cases, drainage through the nasolacrimal duct and
systemic absorption, and consequent side-effects must be carefully monitored.
The conventional formulation approaches discussed above can only increase the retention time on
the ocular surface and does not improve trans-membrane penetration (in the absence of penetration
enhancing formulation components). The complex ultrastructure of the cornea, enzymes, efflux
proteins and the lymphatic and vascular systems, severely limits penetration of the therapeutic
agent across the ocular tissues. Moreover, the ocular tissues are very sensitive; thus, the use of
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permeation enhancers is limited in ophthalmic formulations (13, 14). Therefore, there is a pressing
need for advanced ophthalmic formulations to circumvent the challenges associated with topical
ocular drug delivery.
Prior to looking at the potential formulation strategies, a brief discussion with respect to the
diffusion pathways and the diffusional barriers encountered in topical administration is presented.
Routes of permeation following topical application
Topically administered drugs can penetrate the deeper ocular tissues primarily through two routes
(Figure 1). Transcorneal permeation – commonly referred to as the corneal pathway - is the
predominant diffusional route from the ocular surface into the deeper ocular tissues, especially for
access to the anterior segment tissues (15). However, for efficient transcorneal penetration, the
physicochemical characteristics of the drug must be favorable and a delicate balance between
hydrophilic and lipophilic characteristics is needed. Hydrophilic compounds appear to favor the
non-corneal pathway, which involves permeation across the conjunctiva and sclera (conjunctivalscleral pathway) into the deeper tissues of the eye since the conjunctival epithelium is leakier than
the corneal epithelium. The conjunctival-scleral pathway is especially attractive for targeting the
posterior segment tissues. The conjunctival and choroidal vasculature and lymphatics, however,
rapidly clear drug from these tissues, severely limiting access to the retina and vitreous humor (16,
17).
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Figure 1: Fate of API post-ocular instillation (reproduced from Therapeutic Delivery.
(2018) 9(2), with permission of Future Science Group).
Barriers to Topical Ophthalmic Drug Delivery
Topically administered therapeutic agents, targeting the inner ocular tissues, encounter static,
dynamic and metabolic barriers that limit ocular bioavailability. These barriers can be classified
as precorneal, corneal, and the blood-ocular barriers (18, 19).
Diffusional Barriers
Precorneal Barriers
The precorneal barrier affects both corneal and non-corneal pathways. Tear drainage forms a major
precorneal barrier component (20-22). The conjunctival cul de sac can accommodate
approximately 7-10 µL fluid; thus, a significant portion of the topically administered eyedrop, 3550 µL, is lost (23). Precorneal drainage not only causes the removal of the instilled formulation
(drop/solution) but also reduces the corneal contact time for the formulation (24, 25). Patton, 1977,
reported an inverse correlation between instillation volume and bioavailability (26-28). Also, the
increased tear flow can lead to faster precorneal elimination and decreased efficacy. Osmolarity
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and pH of the formulation are two important parameters that can trigger tear fluid generation (29).
Additionally, tear fluid consists of proteins, to which the drug can bind, reducing the free drug
concentration in the tear fluid (29). Moreover, the multi-layered tear film, with its hydrophilic and
hydrophobic components (30), also presents a diffusion challenge by itself.
Diffusional Barriers in the Corneal Pathway
Corneal Barrier: Cornea is a multi-layered barrier limiting drug penetration into the aqueous
humor through the corneal pathway (17). It has layers with alternative lipophilic and hydrophilic
characteristics; the epithelium (contains 5-6 layers of epithelial cells) and endothelium are
lipophilic in nature, whereas, stroma is hydrophilic in nature. Hence, the pharmaceutical active
should have optimum hydrophilicity/lipophilicity, and other physicochemical characteristics such
as molecular weight, polar surface area, hydrogen bond donors and acceptors, for it to permeate
efficiently across the cornea. Additionally, the corneal epithelial cells express tight junctions that
restrict transcorneal paracellular diffusion, underlining the importance of the physicochemical
characteristics and concentration gradients that govern transcellular, transcorneal diffusion. Efflux
transporters, such as P-glycoprotein (P-gp) and multidrug-resistant proteins (MRPs), expressed on
the corneal epithelium (31) present additional barriers to transcorneal diffusion of their substrates
(19, 32-35). Unlike the epithelial cells, corneal endothelium is leaky in nature, presenting little
restriction to the movement of macromolecules between the stroma and aqueous humor (36). Thus,
the corneal epithelium acts as the major barrier to transcorneal diffusion.
Diffusional Barriers in the conjunctival – scleral (non-corneal) pathway
Drug diffusion into the ocular tissue through the conjunctival-scleral pathway is also challenged.
Although slightly leakier than the cornea (37), the conjunctival epithelium expresses efflux pumps
that limits trans-conjunctival diffusion of its substrates. Since the conjunctiva is highly
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vascularized, unlike the cornea which is avascular, a significant fraction of the drug molecules
penetrating across the conjunctival epithelium is lost into the systemic circulation. Moreover, tear
dilutes the topically administered drop and the blinking action spreads the diluted formulation over
the ocular surface, further decreasing the trans-conjunctival concentration gradient. Thus,
formulations that settle in the conjunctival sac, and is not easily dispersed across the ocular surface,
may utilize the conjunctival-scleral pathway more efficiently. Some recent publications using
topical films/inserts seem to utilize this route of entry into the deeper ocular tissues from the
surface (38).
Drug penetrating across the conjunctiva will reach the sclera from where it can reach the retina.
The sclera is a poorly vascularized tissue comprising of collagen and mucopolysaccharides (39).
Scleral permeability is significantly higher than that of the cornea; however, considering that very
little of the topically administered agent reaches the episcleral region, the concentration gradient
across the sclera will be low. Some portion of the drug can also migrate laterally across the sclera,
which will further decrease the trans-scleral concentration gradient. As a result, following topical
instillation trans-scleral flux can be low, even though trans-scleral permeability may be greater
than transcorneal permeability. Other factors affecting the scleral permeability include molecular
radius, physicochemical properties and the surface charge of the active moiety (40-44).
The above discussion on the various barriers restricting ocular bioavailability of therapeutic agents
following topical application is summarized in Table 1.
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Table 1: Physiological challenges to ocular drug delivery (reproduced from Therapeutic
Delivery. (2018) 9(2), with permission of Future Science Group).
Challenges
Anatomy and
physiological
limitations.

Physico-chemical
limitations.

Ocular and
systemic toxicities.

Effect
 Reduced pre-corneal residence time.
 Frequent dosing required; leading to a reduced patient
compliance.
 Naso-lacrimal drainage leads to drug loss.
 Systemic toxicity.
 Ocular toxicity.
 Reduce trans-corneal flux.
 Poor drug solubility and permeability.
 Drug storage instability leading to reduced efficacy
and increased cost.
 Damage to the ocular tissues (retinal necrosis, loss of
retinal ganglion cells, vitreal inflammation, corneal
edema, neovascularization, and inflammation) and
occurrence of systemic toxicities (hepatoxicity and
nephrotoxicity) and side-effects (gastrointestinal
disturbances) observed.

References
(45-66)

(54, 56, 57,
67-69)
(45,

51-54,

61,

63-66,

70-80)

Metabolism in the ocular tissues
Enzymes (glutathione and related enzymes) form the defense system against foreign chemicals
and oxidative stress, to protect the eyes. Glutathione and glucose-6-phosphate dehydrogenase is
found in lens, cornea, and retina (81). Metabolizing enzymes, such as oxidoreductases,
hydrolases, present in the eye can metabolize the administered drug and thus affect the response
intensity and duration (82). Various enzymes capable of metabolizing therapeutics agents present
in the anterior segment ocular tissues is listed in the Table 2.
Elimination Pathways
The faction of the topically administered agent that reaches the aqueous humor faces additional
elimination mechanisms, in the form of aqueous humor outflow, that limits exposure to the iris-
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ciliary bodies and lens. Aqueous humor turnover leads to loss of the drug through the Canal of
Schlemm and trabecular meshwork and into the systemic circulation through the lymphatic
circulation (83, 84). Diffusion into the microvasculature, present in the various parts of the eye, is
another pathway via which the actives enter the systemic circulation (83, 85). Small lipophilic
molecules are rapidly eliminated in comparison to large hydrophilic molecules ascribed to their
ability to cross blood-aqueous barrier (BAB) and enter the systemic circulation (86).
Table 2: Various metabolizing enzymes expressed in anterior segment ocular tissues
(reproduced from Therapeutic Delivery. (2018) 9(2), with permission of Future Science
Group).
Ocular tissue
Cornea

Iris-Ciliary
bodies
Lens
Conjunctiva

Drug metabolizing enzymes
CYP-1A/2B/2C/3A/4B1, NADPH reductases, ketone
reductases, esterases, arylamine acetyltransferase,
Glutathione S-Transferase. Aldehyde oxidase.
Aldehyde oxidase, Glutathione S-transferase, Esterase,
ketone reductase, CYP-1A/1B1/2B/2C/3A/4B1/39A1.
NaDC3, CYP2B, CYP2C, ketone Reductase
Ketone Reductase, Aldehyde Reductase, CYP2b/3A/4B1, BCRP1.

References
(33, 81, 87,
88)
(81, 87, 88)
(87-89)
(87) (88)

Challenges in polyene-based pharmacotherapy of ocular fungal
infections
Since the past decade there has been a steady rise in the incidences of ocular fungal
infections such as keratitis, endophthalmitis, blepharitis, and conjunctivitis which affect nearly one
million population in the United States, annually (90, 91). Of these, the incidences for fungal
keratitis were the highest with an estimated 930,000 visits to doctor's office and outpatient clinics
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and about 58,000 emergency department visits with about 76.5% of keratitis visits requiring drug
prescriptions (91). Episodes of keratitis and other ocular fungal infections costed an estimated
$175 million in direct health care expenditures, that included $58 million for Medicare patients
and $12 million for Medicaid patients annually in the United States, according to an analysis
reported by Collier et al in Morbidity and Mortality Weekly Report for Centers for Disease Control
and Prevention (91).
This increase in ocular fungal infections has been majorly attributed to the increase in the
population of the immunocompromised patients, rapid emergence of resistance and crossresistance of the fungal species to antifungal agents, and the development of fungal infections due
to more than a single fungal species (92). There are more than 105 different variants of fungi,
encompassing 56 genera, that are known to cause ocular fungal infections such as keratitis,
endophthalmitis, blepharitis, and conjunctivitis (93).
The polyene and azole antifungals have been the mainstay in the pharmacotherapy of invasive
systemic fungal infections due to their broad antifungal spectrum and potent biological activity
(94, 95). The polyene class comprising of amphotericin B, nystatin, and natamycin have been
widely used in therapy owing to their antifungal activity against Candida spp., Aspergillus spp.,
Fusarium spp., Scedosporium spp., and Zygomycetes class of fungi which are the common
causative species for fungal infections (96, 97). The polyene antifungals also report few cases of
emergence of resistance and cross-resistance and the use of lipid-based polyene formulations
(especially amphotericin B) have provided alternatives with greater safety, tolerability, and lower
toxicity profiles (98, 99). Azoles, like the polyenes, exhibit a broad spectrum of activity by eliciting
both fungistatic and fungicidal activity. Azoles show biological activity against C. albicans and
non-C. albicans spp., Fusarium spp., Aspergillus spp., and the Zygomycetes (100, 101).
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Fluconazole is considered to be more cost effective, safe, and tolerable antifungal agent with low
toxicity profile, whereas the other two clinically important azoles, itraconazole and voriconazole,
even though possess a broad spectrum of potent antifungal activity, elicit toxic and adverse sideeffects (102).
These polyene and azole antifungal agents have been used as the front-line therapeutic agents in
invasive fungal systemic infections, onychomycosis, ophthalmic fungal infections, fungal
dermatitis, and meningitis (103-107). However, their use in the ocular fungal therapy has been a
challenge due to the unique ocular anatomy and their physicochemical properties. This is evident
from the fact that, only natamycin has been available commercially for treatment of ophthalmic
fungal infections, and the other antifungals are used off-label (95).
The ocular fungal infections, like the other fungal infections, are on steady surge that necessitate
the introduction of other polyene and azole antifungal drugs as commercial dosage forms that are
potent and make a safe, tolerable, and cost-effective therapy.
Chemistry, mechanism of action, and antifungal activity of the polyene antifungals
Chemistry
Polyenes are characterized by the presence of multiple conjugated double bonds (Figure
2: [i (A)] and [ii(A)]) in a hydroxylated chromophore. Based on the number of the conjugated
double bonds, amphotericin B and natamycin, are classified as heptaene and tetraene polyene
antifungal drugs (108). The conjugated double bond lactone chromophore is known to possess an
all-trans conformation and is essential for the antifungal activity and stability of amphotericin B
and natamycin (109, 110). The conjugated double bonds impart lipophilicity and the hydroxylation
on the chromophore imparts hydrophilicity to the two polyene antifungals. The chromophores of
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both the polyene antifungal drugs (amphotericin B and natamycin) are also characterized by the
attachment of a mycosamine (basic) moiety (Figure 2: [i(B)] and [ii(B)]) via an ether linkage and
carboxylic (acidic) group (Figure 2: [i(C)] and [ii(C)]). These groups impart an
amphoteric/amphipathic character to both the polyenes. The amino group in the mycosamine
moiety exhibits a Ka of about 8.6 whereas the pKa value for the carboxyl group is reported to be
around 4–4.5; rendering amphotericin B and natamycin as zwitterionic species with an isoelectric
point at a pH range of approximately 5-7 (108, 111-113). The mycosamine and the carboxyl
terminals impart a polar character (contribute to the relative insolubility in organic solvents),
whereas the opposite unsaturated terminal imparts a non-polar character (contributes to the
aqueous insolubility) to amphotericin B and natamycin (108, 113).

Figure 2: (i) Amphotericin B, (ii) Natamycin; [(A): Conjugated multiple bonds, (B):
Mycosamine moiety, (C): Carboxylic group] (reproduced from Journal of Ocular
Pharmacology and Therapeutics (2019) 35(1), with permission of Mary Ann Liebert Inc.
Publishers).
Mechanism of action
Fungi are eukaryotic organisms that contain sterols as the essential lipid components which are
responsible for mediating their cellular and physiological functions. Most of these sterols are
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similar to those found in humans; hence, a unique and specific fungal target (that is absent in
human host) is essential for the effectiveness of an antifungal agent (114). Ergosterol, a sterol that
is specifically present in the fungal species and absent in the human hosts, is one of the most
common targets for an antifungal drug to elicit its activity (114, 115). Disruption of the ergosterol
biosynthesis to deprive the fungal species of ergosterol (an essential structural and signaling sterol)
constitutes the predominant mechanism of action of most of the polyene and azole antifungal
agents (116, 117).
Ergosterol is an essential fungal sterol that is responsible for maintaining the membrane fluidity
and integrity and relaying the cellular signals in fungal cells (118). Polyene antifungal drugs are
known to exhibit antifungal activity by binding to ergosterol and inhibiting its cellular functions
with (amphotericin B) or without (natamycin) permeabilizing the fungal membrane (115, 119).
Amphotericin B and natamycin are known to bind to ergosterol and inhibit its cellular activity
leading to a fungicidal action (115, 120, 121). The binding of polyene antifungals to ergosterol
results in inhibiting the ergosterol-dependent membrane fusion and fission processes, endocytosis,
and plasma protein complexes leading to the death of the fungal species (122-128). Additionally,
amphotericin B-ergosterol binding also results in the formation of aqueous pores leading to a
permeabilization of the fungal cell membrane that causes the efflux of potassium and other cellular
components eliciting antifungal activity (129, 130). The binding of amphotericin B to ergosterol
is considered to be a predominant mode of action of amphotericin B in comparison to the
permeabilizing effect that has been considered as a secondary mode of action (130, 131).
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Figure 3: Mechanism of action of polyene antifungal drugs in fungal cells (reproduced
from Journal of Ocular Pharmacology and Therapeutics (2019) 35(1), with permission of
Mary Ann Liebert Inc. Publishers).
Figure 3 illustrates the mechanism of action of polyene antifungal drugs in fungal cells.
Antifungal activity of Polyene antifungals and its comparison with Azoles
Polyene antifungal drugs – amphotericin B and natamycin possess a broad spectrum of antifungal
activity against filamentous and yeast-like fungi (natamycin exhibits weak to moderate action
against the yeast-like fungal forms) (107, 119, 132). Table 3 elaborates on the antifungal activity
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of the two polyene drugs against various fungal species with the minimum inhibitory concentration
(MIC) corresponding to each species.
Table 3: Antifungal activity of amphotericin B and natamycin with their MIC against
various clinically relevant fungal species (reproduced from Journal of Ocular
Pharmacology and Therapeutics (2019) 35(1), with permission of Mary Ann Liebert Inc.
Publishers).
Species/strains
Candida
Aspergillus
Fusarium
Penicillium
Paecilomyces
Rhizopus
Cunninghamella
Others
(Cryptococcus
neoformans, Histoplasma
capsulatum, Blastomyces
dermatitidis, Sporothrix
schenckii, Coccidioides
immitis)

Polyene drugs (MIC: µg/mL)
Amphotericin B
Natamycin
0.25-2
1-2
1-4
5-40
1->4
4-8
1
1-3
0.25->16
2-6
0.5-2
2-6
0.5-2
<4
0.25-4
1-25

Reference
(130, 133-136)
(137-139)
(137, 138, 140)
(122, 141)
(141)
(138, 142)
(141, 143)
(119, 122, 143146)

Amongst the polyene class of antifungal drugs, amphotericin B shows the most potent activity
with low MIC values (< 4 µg/mL) for all the clinically relevant fungal species (with a few
exceptions from Paecilomyces species) that are responsible for the fungal infections in humans
(Table 3). However, in comparison to amphotericin B, natamycin shows less potent activity with
a broad MIC range for the fungal species (Table 3).
Azole class of antifungals, like the polyene group, are broad spectrum antifungal agents. However,
due to the presence of a variety of azole antifungals belonging to different generations; the class
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shows variability in antifungal activity and potency against a variety of fungal species that are
known to cause invasive and superficial fungal infections. Table 4 enlists the fungal species and
MIC of the various azole drugs against them.
Table 4: Antifungal activity of azoles with their MIC against various clinically relevant
fungal species (reproduced from Journal of Ocular Pharmacology and Therapeutics (2019)
35(1), with permission of Mary Ann Liebert Inc. Publishers).
Species/
strains
Candida

FLU
0.5-32

Aspergillus

>64

Azole drugs (MIC: µg/mL)
ITR
KET
MICO
VOR
0.03-4
0.030.02-8
0.03-4
>32
0.5-2.0 0.06-8
1.5-3.5
0.5-2.0

Fusarium

>64

32

Rhizopus
Cunninghamella

>64
>64

0.03-8
0.1252
0.060.5

0.1-50

0.07-40

0.5-8

1-16
>16

1->4
2->4

2->8
8->32

Reference
POS
≤1

(147-149)

0.25- (150-153)
0.5
0.25-16 (150, 154,
155)
1-8
(150, 156)
0.03-1 (150, 156,
157)
0.01-1 (150, 158,
159)

Dimorphic fungi
0.06-32
0.03-8
0.10.03–1
(Histoplasma,
0.001
Blastomyces,
Coccidioides,
Paracoccidioides,
Paracoccidioides,
Sporothrix
species).
FLU: fluconazole; ITR: itraconazole; KET: ketoconazole; MICO: miconazole; VOR:
voriconazole; POS: posaconazole

Posaconazole and voriconazole, belonging to the most recent and newer generation of azoles,
exhibit the highest potency and activity (in vitro, in vivo, and clinical studies) in comparison to all
the earlier generation azole antifungals. Accordingly, posaconazole and voriconazole, have
exhibited superior clinical efficacy and outcomes than the other azole antifungals (156, 158).
Resistance
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The polyene and azole class of antifungals exhibit susceptibility towards the emergence of fungal
resistance like the antibacterial agents. The degree of susceptibility, however, differs between the
two classes, with azole antifungals having greater predisposition to the development of fungal
resistance than the polyene class of antifungals (115). Additionally, the mechanism of resistance
in fungal species against the different classes of antifungal drugs also differs (152).
The occurrence of resistance against polyene antifungals is less prevalent than the azole
antifungals; however, resistance towards amphotericin B is observed in fungal species such as C.
lusitaniae, C. glabrata, C. guilliermondii, A. terreus, and T. beigelii and against natamycin in A.
parasiticus, A. flavus, and C. parapsilosis (115, 119, 160). An increase in the biosynthesis and
accumulation of other sterols, as a replacement for ergosterol, with a concomitant reduction in
biosynthesis of ergosterol (due to a modified and mutated ERG3 gene that causes a reduction in
ergosterol synthesis) in fungal cell membranes has been implicated as one of the major modes for
the development of polyene resistance (161). This has led to the emergence of resistant fungal
species with low ergosterol content for the binding of polyene drugs to elicit their antifungal
activity. Apart from these, replacement, reorientation, and/or masking of some or all the polyenebinding sterols (ergosterol, cholesterol, or stigmasterol) with sterols having less affinity for
polyenes (hindering their binding) has also been credited as one of the major factors in the
emergence of resistance (108). The former reason coupled with decreased a susceptibility to
oxidative damage due to an enhanced catalase activity has been attributed to the development of
resistance against amphotericin B, whereas, the latter reason has been primarily associated with
the emergence of fungal species having an innate resistance against natamycin (119, 160, 162).
In comparison to the polyenes, resistance to azoles has been known to occur via multiple
mechanisms. One of the major underlying mechanism has been the overexpression of active efflux
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pumps due to the upregulation of the CDR (Confluence dependent resistance) and MDR (Multi
drug resistance) genes that has led to a decreased concentration of the azole antifungal drugs within
the fungal cells (due to their efflux) contributing to the emergence of resistance (163, 164).
Mutations in the ERG11 gene that encodes the target enzyme (lanosterol C14α-demethylase)
results in the alteration in the structure and chemistry of the enzyme that leads to a hindrance in
the efficient binding of the azole drugs to the enzyme that causes the emergence of resistance
against them (160). In some cases, just like the polyene antifungals, mutation of ERG3 genes
leading to the inhibition of ergosterol biosynthesis and increase in the biosynthesis and
accumulation of other sterols in the fungi has also been implicated as a predominant mode of
development of resistance against azole drugs (165). Apart from these, upregulation of the ERG11
gene responsible for the coding of target enzyme also occurs, leading to an increase in the target
enzyme concentration in the fungal cells, thereby providing resistance against the azole drugs
(166). Figure 4 provides an overview of the mechanism of resistance against polyene and azole
antifungals that occurs in fungal cells.
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Challenges to the ocular delivery of polyene and azole antifungals
Anatomical and physiological limitations
Topical route is the most preferred route for the administration of drugs in treating the ophthalmic

Figure 4: Schematic representation of the development of resistance against polyene and
azole antifungals manifested in fungal species (reproduced from Journal of Ocular
Pharmacology and Therapeutics (2019) 35(1), with permission of Mary Ann Liebert Inc.
Publishers).
infections and diseases. However, in treating the ocular fungal infections, the severity and
localization of the fungal infection in ocular tissues dictates the route of drug administration (167).
For example, most of the fungal infections of the anterior chamber are treated by administering
the drugs topically, whereas in case of endophthalmitis or deep-seated mycoses, parenteral or
intraocular injections are routinely employed (167).
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Targeting of antifungal drugs, especially polyene and azole antifungals, to the different infected
ocular sites is still one of the formidable challenges associated with antifungal pharmacotherapy
(168). This has been primarily attributed to the complex anatomy of the eye and the
physicochemical properties of the various classes of antifungal drugs.
Anatomical and physiological barriers pose significant challenges to the topically administered
formulations of polyene and azole antifungals (76, 169). The anatomical barriers comprise of the
different layers of cornea, sclera, retina, and blood-retinal and blood-aqueous barriers whereas,
ocular blood flow, lymphatic clearance, tear dilution, and ocular enzymes and transporters
constitute the physiological barriers (170-172). These barriers collectively affect the ocular
pharmacokinetics of all the ocularly administered drug (173). The cornea, iris-ciliary, and sclera
act as barriers to the permeation of the drug when administered topically for various drugs such as
amphotericin B, natamycin, miconazole, ketoconazole, and fluconazole (76, 168, 174). Bloodaqueous barrier (BAB) and blood-retinal barrier (BRB) collectively form the blood-ocular barriers
for the entry of drugs into the posterior chamber (168). BAB is composed of the endothelial tight
junctions present in the iris and ciliary epithelium. BAB inhibits the movement of drugs such as
amphotericin B, natamycin, and ketoconazole into the posterior ocular milieu due to its tight
cellular integrity (175-177). In case of severe inflammation or infection such as fungal
endophthalmitis, BAB gets disrupted facilitating the passage of solutes or drugs through it. Hence,
in cases of severe fungal keratitis topically administered amphotericin B, fluconazole,
itraconazole, and ketoconazole are found to easily penetrate the cornea and BAB (attributed to the
loss of corneal integrity due to inflammation and keratitis) to enter the posterior chamber in
contrast to the insignificant or no penetration of the drug in healthy individuals (167, 178, 179).
BRB hinders the penetration of solutes and drugs from entering the retina and posterior chamber
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from the blood (76, 167, 179). The retinal blood vessels and chorioepithelial cells form the inner
BRB and retinal capillary endothelial cells and retinal pigment cells form the outer BRB. Retina
acts as a vascular barrier to the permeation of drugs having molecular weight greater than 76 kDa,
including the polyene and azole category antifungals, into the posterior chamber in case of
parenteral administration of the drug (70). The anatomical barriers are significantly responsible
for altering the drug penetration, bioavailability, and intraocular concentration (175, 180-182).
The physiological barriers, also known as the dynamic barriers, act as hindrances to the ocular
delivery of drugs. Topical application of polyene and azole drugs as a solution or a suspension
leads to considerable losses due to the naso-lachrymal drainage (183-185). Additionally, the tear
film is also responsible in reducing the topical residence time of the antifungal drugs as the tear
film is replaced every 2-20 mins in human eyes (175, 186). To overcome these losses, higher drug
concentrations are instilled which lead to adverse side-effects and toxicity at the ocular site,
particularly in the case of amphotericin B and ketoconazole, thereby establishing a threshold for
the maximum concentration of the antifungal that can be instilled into the eye (168). The tear film
is also responsible for affecting the ocular drug pharmacokinetics by binding to the drugs. The tear
film, composed of mucin, salts, enzymes, and proteins, has been shown to bind anti-infective drug
classes such as antifungals and antibacterials, there-by posing as a challenge to their ocular
therapeutic delivery (83, 175, 187-189). Additionally, the lipoidal tear film also poses as a barrier
for the diffusion of hydrophilic drugs (such as fluconazole and natamycin) via the cornea, thereby
reducing the drug penetration into the inner ocular tissues (83, 175, 190).
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Figure 5: Brief overview on the anatomical and physiological ocular barriers that
compromise the ocular pharmacokinetics of the drugs (reproduced from Journal of Ocular
Pharmacology and Therapeutics (2019) 35(1), with permission of Mary Ann Liebert Inc.
Publishers).
Figure 5 provides a brief overview on the anatomical and physiological ocular barriers that
compromise the ocular pharmacokinetics of the drugs.
Physicochemical limitations
The physicochemical properties of drugs affect their ability penetrate the ocular barriers to reach
their site of activity in the ocular milieu. One of the major challenges associated with the antifungal
agents is their large molecular weight and poor aqueous solubility (168, 169). The ocular delivery
of amphotericin B is challenging due to its high molecular weight and low aqueous solubility
which hinders its penetration across the cornea and blood-retinal barrier, which severely limits its
ocular bioavailability (168). The reduced bioavailability of itraconazole and natamycin due to poor
corneal penetration has also been attributed to their high molecular weights (167). Additionally,
binding of itraconazole to the proteins in the tear-lipoidal film and high hydrophobicity have
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contributed to its poor corneal penetration upon topical administration (167, 168). Ketoconazole
and miconazole have also exhibited poor penetration across the cornea and blood-retinal barrier
due to their high molecular weights, hydrophobic characters and tendencies to undergo protein
binding (168). Voriconazole, even though has a broad and potent spectrum of activity in ocular
fungal infections, its ocular use is limited due to the visual disturbances that have been exclusively
associated as a side-effect with this azole drug (168). Thus, high molecular weight, high
hydrophobic character, and poor aqueous solubility have been the major physicochemical
challenges to the ocular delivery of polyene and azole antifungal drugs.
Selective potent antifungal activity
Selective potent action of polyene and azole antifungals is one of the major challenges associated
with their monotherapy. This is observed from the MIC values for these drugs that have been
elaborated in Table 1 and 2. The potent selectivity in their antifungal activity has been abundantly
evidenced and discussed in literature. Amongst the polyene class of antifungals, natamycin is
known to have a potent activity against filamentous fungi such as Aspergillus and Fusarium but
only a weak to moderate activity against the yeast-like fungi (76, 95, 119). This has led to the use
of natamycin as a front-line therapy drug in treating superficial ocular fungal keratitis caused by
Fusarium and Aspergillus species (119). In treating fungal keratitis complicated by both
filamentous and yeast-like fungal species, multiple antifungal drug regimen is initiated using
natamycin concomitantly with miconazole, itraconazole, ketoconazole, or fluconazole (191).
Similarly, amphotericin B has shown variability in its activity against the filamentous fungal
species, especially Fusarium species, and shown a potent activity against the Candida species
(179). This has led to its frequent use as an off-label antifungal agent in treating the cases of severe
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Candida keratitis but not in cases of Fusarium keratitis in which natamycin is preferred (93).
Fluconazole also is known to have weak to moderate action against the filamentous fungi but
excellent action against Candida species making it an ideal agent in the treatment of deep-seated
Candida keratitis and not a preferred candidate in the therapy of filamentous fungi caused keratitis
(179, 192). Itraconazole and miconazole show variable activity against the filamentous fungal
species with a potent activity against Aspergillus species and a weak activity against Fusarium
species making it suitable candidate in treating deep-seated Aspergillus infection but not in the
case of Fusarium infections (179).
Ocular and systemic drug toxicity
The polyene and azole antifungals are known to elicit ocular and systemic toxicities which
manifests as one the challenges associated with their therapy. In a toxicity evaluation by Foster et
al., the ocular toxicity of the clinically used polyene and azole antifungals (amphotericin B,
flucytosine, miconazole, and ketoconazole) was studied on debrided rabbit cornea, in vivo, upon
topical application of these antifungals as 1% solutions or suspensions (193). The evaluations were
based on rate of closure of the debrided epithelial corneal wounds, quality of regenerating
epithelium, stromal edema and haze, and iritis (visual and microscopic evaluations). It was found
that amphotericin B severely retarded the rate of debrided corneal closure and manifested dramatic
pathologic changes (evaluated on the bases of scores for quality of regenerating epithelium,
stromal edema and haze, and iritis) which worsened each day with the continuation of therapy.
However, ketoconazole, flucytosine, and miconazole produced histologically undetectable
changes; indicating their relative efficacy and safety in antifungal therapy involving corneal
debridement (in diseases such as fungal keratitis and endophthalmitis). The ocular toxicity of
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amphotericin B has also been corroborated by various studies, in which, it has shown to cause
retinal toxicity, loss of retinal ganglion cells, vitreal inflammation, corneal edema,
neovascularization, and inflammation, upon its prolonged and frequent use as intraocular
injections (71-75). Similarly, itraconazole and voriconazole are known to cause retinal necrosis
and visual disturbances upon their intraocular injections and oral use, respectively (77-79).
Systemic side-effects/toxicities such as nephrotoxicity (amphotericin B), hepatotoxicity
(ketoconazole and voriconazole), and gastrointestinal upsets (itraconazole) are also commonly
encountered upon their oral and/or intravenous administration in ocular fungal infections (45, 70,
76, 77). Hence, from the above-mentioned discussion it is evident that ocular and systemic
toxicities manifest an important challenge in their ocular delivery.
Emergence of resistance and cross-resistance
Antifungal resistance has been one of the major challenges associated with the antifungal drug
consortium; particularly with the azole antifungals (160). Clinical instances of primary and
secondary resistances are observed for the different antifungal drugs (160). Polyene antifungals
are generally associated with primary resistance, meaning, some of the fungal species are
inherently and naturally resistant to them. Such a kind of primary or intrinsic resistance is observed
against amphotericin B in C. lusitaniae, A. terreus, and T. beigelii and against natamycin in A.
parasiticus, A. flavus, and C. parapsilosis (119, 150, 194, 195). Azoles in contrast to the polyene
drugs exhibit both primary and secondary resistance (resistance due to a prolonged exposure of
the fungal species to the azole antifungals) (107). For example, C. krusei is known to be resistant
towards fluconazole and secondary resistance is emerging in C. albicans and C. glabrata against
fluconazole at a rapid pace due to the continuous clinical use of fluconazole (107, 196).
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Additionally, cross-resistance has also been one of the challenges plaguing the use of azole drugs.
Widespread and continuous use of itraconazole and fluconazole has resulted in the development
of resistant species against them and also against other antifungals (107, 115, 160). The emergence
of resistance and cross-resistance against the newer azoles like voriconazole is emerging with
reports of voriconazole resistant Fusarium keratitis and Aspergillus ocular fungal infections being
reported. Use of posaconazole instead of voriconazole in the former case and surgical method in
the latter, helped in overcoming the challenge of resistance associated with voriconazole (197,
198). Currently, posaconazole is considered to be one of the most suitable therapies in cases of
resistant fungal keratitis and other refractory ocular fungal infections (197-199).
Lack of robust clinical in vitro susceptibility testing
One of the challenges associated with antifungal agents, especially azole drugs, is the lack of
clinical in vitro susceptibility testing that provides a robust in vivo correlation. This is owing to
the fact that the in vitro susceptibility testing with fungal species is not yet standardized, and the
results of in vitro tests do not always compare to the results obtained in vivo (107). The absence
of the standardized tests for in vitro susceptibility testing in mycotic keratitis is attributed to
small sample sizes, non-uniformity of MIC data due to the presence of various in vitro
susceptibility testing methods and focus on one particular species (200). One such challenge has
been observed in the evaluation of the most suitable polyene and/or azole antifungal in treating
Fusarium keratitis due to the MIC variability for the different polyene/azole antifungals between
and within the different Fusarium strains that cause the ocular keratitis (154). Similar case has
been frequently observed for fluconazole, which shows a weak in vitro activity against Candida
and C. neoformans isolates but a potent in vivo activity against them (158). This has been
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attributed to the lack of standardized in vitro susceptibility testing methods for the antifungal
agents. Sensitive, specific, reliable, reproducible, and standardized in vitro susceptibility testing
methods are warranted for the accurate and timely diagnosis of fungal infections, particularly
fungal keratitis, to avoid treatment failures and relapses with the polyene and azole drug based
ocular pharmacotherapy (154).
Approaches at overcoming the challenges for the ocular delivery of polyene antifungal
drugs
Drug delivery and formulation approaches have been one of the most preferred options for
overcoming the anatomical and physiological ocular barriers, physicochemical challenges, and
ocular and systemic toxicities/side-effects associated with the polyene and azole drugs. One of the
primary routes that has been undertaken to overcome the anatomical barrier associated reduced
drug penetration is the improvement in the pre-corneal residence time of the formulation to
improve the drug penetration by a prolonged contact upon topical application and/or by using
intraocular injections (168).
To improve the ocular bioavailability and safety of amphotericin B, both, formulation and
alternative drug delivery approaches were utilized to overcome the anatomical and physiological
barriers (45). Different lipoidal formulations (amphotericin B lipid complex (ABLC), liposomal
amphotericin B (L-AMB), and amphotericin B deoxycholate (D-AMB)) of amphotericin B were
developed and evaluated for their ocular penetration, biodistribution, and safety in rabbit eyes, in
vivo, after intravenous administration. It was found that all the amphotericin B lipoidal
formulations penetrated the blood-retinal barrier in the inflamed eyes and the concentration of
amphotericin B following L-AMB administration was approximately 8 times more than ABLC
and D-AMB formulations. So also, it was found that L-AMB reached higher concentrations and
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was safer, in both, the aqueous and vitreous chambers, than the ABLC and D-AMB formulations
upon intravenous administration. This study demonstrated the utility of liposomal amphotericin B
formulations upon intravenous administration in deep-seated fungal infections and/or fungal
inflammations, as an alternative to the topical administration of amphotericin B. In yet another
study, amphotericin B lipid emulsion was found to penetrate the corneal barrier upon topical
instillation and was shown to be safer than the marketed amphotericin B formulation (Fungizone®)
upon multiple instillations (one instillation at every hour for 6 hours) in rabbits, in vivo (46). The
improved bioavailability and safety associated with liposomal formulations of amphotericin B in
comparison to marketed amphotericin B (Fungizone®) was also corroborated by Barza et al. and
Tremblay et al., in in vivo studies carried out on rhesus monkeys and rabbits, respectively (47, 48).
In two independent studies, positively charged amphotericin B loaded Eudragit® RL100
nanoparticles and positively charged chitosan/lecithin nanoparticles exhibited greater corneal
penetration due to an improvement in the pre-corneal residence time and bioavailability by
providing mucoadhesion in rabbit eyes, in vivo (49-51). Apart from providing significantly higher
corneal penetration to the marketed amphotericin B formulation (Fungizone®), the nanoparticles
also exhibited sustained release and potent antifungal activity against Fusarium Solani, Candida
albicans, and Aspergillus fumigatus, in vitro.

To overcome the aqueous solubility

physicochemical challenges, Serrano et al. prepared γ-cyclodextrin complexed amphotericin B
solution (67). The formulation was found to be significantly more stable (physical and chemical
stability) with an improvement (approximately 35%) in its in vitro antifungal activity against
Candida albicans compared to the marketed Fungizone® formulation.
Nanoparticulate approaches have also been utilized to overcome the anatomical and physiological
challenges that are associated with the ocular delivery of natamycin and to target the antifungal
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drugs to overcome their ocular and systemic toxicities. In the study by Bhatta et al. and Chandasana
et al., lecithin/chitosan nanoparticles encapsulating natamycin and poly-D-glucosamine (PDG)
functionalized polycaprolactone (PCL) nanoparticles (PDG-PCL-NPs) encapsulating natamycin
were developed with the aim of improving the ocular residence time and providing a sustained
release of natamycin (52, 53). Upon in vitro evaluation, it was found that the natamycin release
was sustained over seven and eight hours, respectively, for both the nanoparticulate carriers in
comparison to the marketed formulation (natamycin suspension). In vivo evaluations revealed that
the antifungal potency of the nanoparticles and the marketed natamycin suspension was
statistically non-significant. The ocular pharmacokinetic studies demonstrated statistically higher
concentration of natamycin from the nanoparticles in comparison to the marketed suspension
(observed from a higher AUC0-∞ for nanoparticles than the suspension) and a lower clearance at
the pre-corneal sites. The mucoadhesive property of the nanoparticles was attributed to be the
reason for improved bioavailability and for overcoming the ocular anatomical challenges. and in
vivo. Additionally, natamycin loaded niosomes delivered using an in-situ gel showed a safe
(absence of any signs of ocular irritation and/or inflammation in rabbit eyes, in vivo) and sustained
release of natamycin over 24 hours in comparison to the marketed natamycin suspension upon
both in vitro and ex vivo evaluation (54). All these formulations exhibited significantly higher
safety in comparison to the marketed natamycin suspension in rabbits, in vivo. Apart from these,
several other approaches such as improving the aqueous solubility of natamycin by complexing
them with cyclodextrins, formulating them in different lipid formulations are also being actively
worked upon as potential ways to circumnavigate the physicochemical challenges associated with
its ocular delivery (68, 119).
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To overcome the challenges associated with the development of resistance and potential
therapeutic relapse associated with monotherapy, usually, combination antifungal therapy is
initiated (201). The data, however, remains scarce in this regard due to quick replacement and/or
substitution of one antifungal drug with the other in cases of development of resistance and/or
relapse (76). Generally, to overcome the relapse of Candida infections posaconazole and
caspofungin combination therapy is initiated, whereas, posaconazole and voriconazole, and
anidulafungin and posaconazole, combinations are frequent approaches for treating A. fumigatus
infections effectively (202). Similarly, more effectiveness was observed against Fusarium species
when amphotericin B was used in combination with terbinafine and itraconazole in comparison to
its lone use, in vitro, indicating amphotericin B concomitant therapy with terbinafine and
itraconazole could be more efficacious clinically (203). Itraconazole and micafungin combination,
5-flucytosine and amphotericin B, and voriconazole and anidulafungin combination have also
shown superior clinical activity and efficacy in comparison to itraconazole, 5-flucytosine, and
voriconazole monotherapies in systemic fungal infections indicating that these combinations could
also be utilized in ocular fungal infections (119, 204).
Combination therapy is also a preferred choice to overcome the challenge of resistance associated
with antifungal pharmacotherapy (76). Amphotericin B and fluconazole combination have shown
efficacy in the treatment of keratomycosis and in reducing the clinical cases of relapse in
comparison to the monotherapies with the antifungals (205).
Table 5 summarizes the challenges that are associated with the ocular delivery of polyene and
azole antifungals and also enlists the possible approaches/alternatives to overcome the challenges.
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Table 5: Summary of the challenges and possible approaches at overcoming the challenges
associated with the ocular delivery of polyene and azole antifungal drugs (reproduced from
Journal of Ocular Pharmacology and Therapeutics (2019) 35(1), with permission of Mary
Ann Liebert Inc. Publishers).
Challenges
Anatomy
and 
physiological
limitations.






Physicochemical 
limitations.



Ocular
systemic
toxicities.

and 

Effect
Reduced
pre- 
corneal residence
time.
Frequent
dosing
leading
to
a
reduced
patient
compliance.
Drug losses due to 
naso-lachrymal
drainage.
Systemic toxicity.
Ocular toxicity.


Reduce
trans- 
corneal flux.
Poor
drug
solubility.
Drug
storage 
instability leading
to reduced efficacy
and increased cost.


Damage to the 
ocular
tissues
(retinal necrosis,
loss of retinal

Approach
Delivery of drugs using novel
drug delivery systems such as
nanoparticles, films, liposomes,
mucoadhesive
formulations,
ocular implants, etc., for
targeting of drugs to the ocular
site.
Use of excipients such as
chitosan, poloxamer, EDTA to
improve
the
pre-corneal
residence times and enhance the
drug penetration.
To deliver the drugs as gels and
viscous
suspensions
and
emulsions to improve the precorneal residence time and
reduce
the
naso-lachrymal
drainage.
Use of above-mentioned novel
drug delivery systems for the
delivery of polyene and azole
antifungals.
Use of salt forms of drugs, their
complexation
with
cyclodextrins, etc., to improve
their aqueous solubility.
Encapsulation of drugs in
surfactant and lipid core (in case
of niosomal drug delivery) for
improving its trans-corneal
permeation and/or flux.
Ocular targeting of drugs for
treating of the ocular fungal
infections using novel drug
delivery systems such as lipoidal
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Challenges

Selectivity
antifungal
activity.

in 


Resistance and 
cross-resistance.




Effect
ganglion
cells,
vitreal
inflammation,
corneal
edema,
neovascularization,
and inflammation)
and occurrence of
systemic toxicities
(hepatoxicity and
nephrotoxicity)
and
side-effects
(gastrointestinal
disturbances)
observed.
Efficacy
of
pharmacotherapy
is reduced and
chances of relapse
increase.
Long-term
treatment required.
Limited activity of
a drug against a
given
fungal
species/strain.
A class/category of
drug
rendered
inactive
against
fungal
species/strains.
Increase in severity
of the infection
over the time.

Approach
References
drug delivery systems, gels,
nanoparticles, etc.




Combination therapy is initiated. (202-205)
Newer generation of antifungals
such
as
posaconazole,
ravuconazole,
echinocandins,
etc., are used.




Combination therapy is initiated. (202-205)
Newer generation of antifungals
such
as
posaconazole,
ravuconazole, echinocandins,
etc., are used.

Overall objective
The overall objective of this project is to develop an amphotericin B loaded formulation for ocular
drug delivery and to treat severe ocular infections. For these purposes, formulation ought to have
certain properties, such as sterility, compatible with preservative for multidose regimen,
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enhanced permeation, prolonged precorneal retention to reduce frequency of dosing (to prevent
adverse systemic effects and patient compliance), retain/enhance anti-fungal activity of pure
drug, and safety. Keeping these desirable characteristics in mind, we aimed to fabricate
nanostructured lipid carriers for amphotericin B. Amphotericin B is a potent polyene anti-fungal,
a choice of drug for severe ocular fungal infections. The formulations were optimized and evaluated
for its stability, autoclavability, and ex vivo/ in vivo to demonstrate feasibility of nanostructured lipid
carriers for ocular drug delivery. These nanoparticles’ in vitro antifungal activity and cytotoxicity
were evaluated. This project also highlights utility of PEGylation to stabilize drug loading in the
nanoparticles. Various surface modifications, such as chitosan coated nanostructured lipid carriers
and gel entrapped PEGylated nanoparticles, were also studied to deliver and prolong precorneal
residence of amphotericin B. Additionally, effect of preservative (Benzalkonium chloride) was
studied on amphotericin B formulation’s physical and chemical stability. To compare precorneal tear
fluid kinetics, non-compartmental analysis was applied.

Specific aims
Develop nanostructured lipid carriers for ocular drug delivery of amphotericin B and study effect of
PEGylation on the nanostructured lipid carriers. To fabricate, optimize, stabilize, and evaluate ocular
biodistribution of amphotericin B loaded PEGylated nanostructured lipid carriers for ocular drug
delivery.


Demonstrate stability enhancing effect of mPEG-DSPE and effect of PEG lengths on drug
loading.



Optimize amphotericin B-loaded PEGylated nanostructured lipid carriers and study its effect
on formulation characteristics using Design of Experiments approach.
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Effect of autoclave sterilization cycle on the formulation’s physico-chemical characteristics.



Demonstrate four-week stability of the optimized system.



Fabrication and characterization of gel entrapped chitosan coated- and PEGylatedamphotericin B loaded nanostructured lipid carriers.



Study effect of gel entrapped chitosan coated- and PEGylated- amphotericin B loaded
nanostructured lipid carriers on precorneal retention and amphotericin B permeation.



Study effect of preservative (Benzalkonium chloride) on physical and chemical stability of
amphotericin B formulations.



Evaluate ocular biodistribution of these nanostructured lipid carriers in New Zealand rabbits
upon multiple dosing.

48

CHAPTER II
Optimization, Stabilization, And Characterization of Amphotericin B
Loaded Nanostructured Lipid Carriers for Ocular Drug Delivery
Introduction
Ocular fungal infections, if not treated in time, lead to permanently impaired vision and can be
life-threatening in certain cases, especially immunocompromised patients (206). Currently,
natamycin ophthalmic suspension is the only approved and commercially available formulation
that is used to treat infected superficial ocular tissues (Keratomycosis). Natamycin, however, is
not very effective against Candida, which is the most common fungal species causing ocular
fungal infection (207). Once treatment failure with natamycin is observed, physicians switch to
other off-label topical antifungals or systemic therapy (208). Treatment of infections caused by
deep-rooted fungi require potent antifungals, such as amphotericin B (AmB), fluconazole, and
voriconazole (209), either alone or in combination (administered topically or systemically) (207).
AmB is a potent polyene anti-mycotic and drug-of-choice to treat infections caused by invasive
pathogenic fungi, such as Candida spp., Aspergillus fumigatus, Cryptococcus neoformans, and
protozoan parasite Leishmania spp. (207, 210). The newer generation azole antifungals, such as
fluconazole, voriconazole, and posaconazole, have similar potency and better ocular permeation
in comparison with AmB but retain major disadvantages of the azole class of antifungals:
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resistance and cross-resistance (207, 210-212).
Despite the potency and clinical utility of AmB, there are various challenges in ocular delivery of
AmB, which needs to be addressed to allow its transition into therapeutics. It is extremely
lipophilic; practically insoluble in water, methanol, and ethanol; with a molecular weight of 924.1
Daltons; and a log P of 0.8, making it challenging to formulate an effective dosage form. In
addition to these challenges, ocular permeation of AmB and ocular barriers—such as tear turnover,
the complex ultrastructure of the cornea, various metabolizing enzymes, and efflux transporters—
also manifests as formidable barriers (6, 213, 214).
Currently, there is no approved ophthalmic AmB formulation in the market. Thus, in cases of
severe fungal infection, the marketed preparations for intravenous administration (freeze-dried
powders) reconstituted in sterile water or saline are used. However, the marketed preparations
post-reconstitution needs to be used within a day, if stored at room temperature in a dark room, or
1 week if stored at 4oC following reconstitution with sterile water for injection (as per the
instruction from the manufacturer). Furthermore, AmB marketed formulations are incompatible
with preservatives (bacteriostatic agents) and electrolytes (sodium chloride) making development
of multi-dose formulations impractical with current formulation strategies (215).
In recent years, nanoparticulate dosage forms have emerged as a promising ocular formulation
platform for poorly water-soluble compounds due to enhanced retention on the ocular surface as
well as better penetration into the ocular tissues. A few attempts have been made to fabricate AmB
formulations for ocular drug delivery, such as Eudragit® nanoparticles, chitosan and lecithinbased nanoparticles (216), micro-emulsion (217), cyclodextrin-poloxamer nanoparticles (218220). These reports have presented in vitro anti-fungal activity, drug release profiles, ocular
irritation studies and pre-corneal residence kinetics. However, evaluation of stability, safety, and
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biodistribution in animal models (proving suitability for ocular drug delivery) have been lacking
in these studies. Furthermore, effect of sterilization on the nanoparticulate formulations and
residual organic solvents are also lacking.
Lipid nanoparticles enhances drug loading and permeation of the lipophilic molecules (221).
Mucoadhesive, stable, and stealth nanoparticles are achieved with surface modifying agents, such
as polyethylene glycol (PEG), chitosan, lipids with the amine functional group, etc. PEGylation
renders the surface of the nanoparticles hydrophilic; It enhances ocular bioavailability by
interacting with mucous and epithelium of the cornea (222-224). It stabilizes nanoparticles (stearic
stabilization) as well as drug in the nanoparticles by reducing contact with the surroundings
(enzymes, oxidants, other degradation causing agents) (222, 225-227). PEGylation can either be
attained by conjugation (mPEG-DSPE) or electrostatic interaction (PEG-SH) with the lipid (223,
224, 227, 228). The major advantage of conjugated PEG is to prevent dissociation of the PEG over
time in the aqueous environment (222).
The current work focuses on formulating and stabilizing amphotericin B-loaded nanostructured
lipid carriers (AmB-NLC) by PEGylating using optimum PEG molecular weightand optimizing it
for ocular drug delivery. A 4-week stability (physical and chemical), in vitro transcorneal
permeability, in vitro antifungal efficacy and cytotoxicity, and in vivo ocular distribution following
topical administration in rabbits for optimized formulations was evaluated. So far, only a couple
of reports on AmB lipid nanoparticles (1, 2) have been published; however, this would be the first
attempt to formulate and optimize (design of experiment approach) PEG-NLC-AmB for ocular
drug delivery with: an enhanced drug load, an organic solvent-free process, and using a highpressure homogenizer—which facilitates production scale-up.
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Materials and methods
Materials
AmB was purchased from Cayman Chemicals Pvt. Ltd. (Michigan, US). The solid lipids
(CompritolTM 888 ATO, PrecirolTM ATO 5, GeleolTM, DynasanTM 114, DynasanTM 116,
GelucireTM 43/01, GelucireTM 44/14, GelucireTM 50/13) and liquid lipids (LabrafilmTM, MaisineTM,
and Capryol 90TM) were gift samples from Gattefossé (Weil and Rhein, Germany). DSPE-PEG2K-(N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3phosphoethanolamine- mPEG-2000-DSPE) was obtained from Lipoid GmbH (Germany). All
other molecular weight mPEG-DSPE were obtained from Creative PEGWorks® (Chapel Hill, NC,
USA). Surfactants, olive oil, castor oil, oleic acid, and analytical grade solvents were procured
from Fisher scientific (Massachusetts, US). Whole eyes of male albino New Zealand rabbits for
the transcorneal study were procured from Pel-Freez® Biologicals (Rogers, AR, USA).
Lipid screening
Lipid screening was performed to identify a solid and liquid lipid with highest AmB solubility
and/ or dispersibility; without forming aggregates upon cooling. One gram of each lipid was
weighed and heated to 75oC in scintillation vials. To these lipids, AmB was added in small
accurately weighed portions with constant stirring. The mixture was cooled to room temperature
and assessed for drug aggregation as well as homogeneity, with the naked eye and under the
microscope.
PEG Screening
Various molecular weight of PEG in DSPE-PEG (1K, 2K, 5K, 10K, 20K) were screened by
forming PEG-NLC-AmB using these molecular weights (223). These formulations were compared
for physical stability of the formulation (Table 6).
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Table 6: Preliminary experiment with PEGylated and non-PEGylated NLCs.
Ingredients
Lipid Phase
PrecirolTM ATO 5
Castor Oil
mPEG-DSPE. Na salt*
Cremophor EL
Amphotericin B
Aqueous phase
Tween 80
Poloxamer 188
Glycerin
Water

Non-PEGylated NLC (%w/v)

PEGylated NLC (%w/v)

3
1.5
0
1.5
0.1

3
1-3
1.5
0
0.1-0.3

0.8
0.3
2.5
QS

0.8
0.3
2.5
QS

Fabrication of PEGylated and Non-PEGylated NLC
AmB-NLC were prepared using the formula in Table 7. The lipid phase along with AmB was
heated to 75oC and a coarse emulsion was formed by dropwise addition of the aqueous phase to
the lipid phase under magnetic stirring at 2000 rpm. Further, the ULTRA-TURRAX® T 25 (IKA
works INC., NC, USA) was used to homogenize the coarse emulsion into a fine emulsion at 16000
rpm (temperature: 60o C). This fine emulsion was homogenized (temperature: 50o C) at 1500 bars
for 5-15 mins in high-pressure homogenization (HPH) (Emulsiflex C5-Avestin, Canada). The
amphotericin B loaded PEGylated nanostructured lipid carriers (PEG-NLC-AmB) were prepared
by substituting Cremophor® EL with mPEG-DSPE (desired PEG molecular weight) in the lipid
phase.

Ingredients
Lipid Phase
PrecirolTM ATO 5
Castor Oil
mPEG-DSPE. Na salt*
Cremophor EL
Amphotericin B

Table 7: NLC and PEGylated NLC.
Non-PEGylated NLC (%w/v)
PEGylated NLC (%w/v)
3
1.5
0
1.5
0.1

3
1-3
0.75-2.25
0
0.3
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Aqueous phase
Tween 80
0.8
0.8
Poloxamer 188
0.3
0.3
Glycerin
2.5
2.5
Water
QS
QS
*Mol. Wt of mPEG in mPEG DSPE (1K, 2K, 5K, 10K, and 20K) chosen as required.

PEGylated NLC optimization
A three-level response surface design (Box-Behnken Design) was used to optimize the PEGylated
NLC for maximum drug loading, minimum particle size, and Polydispersity index, with a reduced
number of trials without compromising on efficiency and accuracy (229). In this experiment, 3
formulation (DSPE-PEG-2K, AmB, castor oil) and one process parameter (no. of cycles of HPH)
were varied to study its effect on particle size, PDI, entrapment efficiency, and drug loading (Table
8, Table 9). The experimental design was generated and analyzed using Design Expert® version 8
(Stat-Ease, INC, MN, US).
Table 8: Design factors.
Factors/Independent variables/Predictors
Coded

DSPE PEG 2000 Amphotericin B No of cycles Castor oil

Level

% (x1)

% (x2)

(x3)

% (x4)

Low (-1)

0.75

0.1

5

1

Medium (0) 1.5
High (1)
2.25

0.2

10

2

0.3

15

3

Table 9: Box-Behnken design layout.
Factor 1

Factor 2

Factor 3

Factor 4

Run A: DSPE PEG 2000 B: Amphotericin B C: No of cycles D: Castor oil
mg

mg

in HPH

mg

1

300

20

10

4

2

150

20

20

4

3

150

40

20

2
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4

300

20

30

4

5

300

20

20

6

6

450

40

20

6

7

300

40

10

6

8

150

40

10

4

9

450

60

20

4

10

300

40

20

4

11

300

60

10

4

12

300

60

20

2

13

300

40

30

2

14

300

40

10

2

15

300

40

30

6

16

300

20

20

2

17

150

60

20

4

18

150

40

20

6

19

300

60

30

4

20

300

60

20

6

21

150

40

30

4

22

450

40

30

4

23

450

20

20

4

24

450

40

10

4

25

450

40

20

2

High-pressure liquid chromatography (HPLC) analysis
AmB was quantified using a previously published HPLC method with some modifications (230).
HPLC used was a Waters 717 plus auto-sampler coupled with a Waters 2487 Dual λ Absorbance
UV detector, a Waters 600 controller pump, and an Agilent 3395 Integrator. A Phenomenex
Luna® PFP (2) column with 5µ packing and dimensions 4.6 mm × 250 mm was used for the
analysis. The mobile phase was 0.05 N sodium acetate and acetonitrile mixed with the ratio of 7:3.
The retention time for AmB was 11.6 min, detected at the wavelength (λmax) of 407 nm. The
standard curve of AmB, ranging from 0.1 µg/mL to 20 µg/mL, was prepared with a mixture
containing equal proportions of dimethyl sulfoxide (DMSO) and methanol. The method was
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validated for precision (inter- and intra-day), accuracy, linearity, limit of quantification, and limit
of detection.
Bioanalytical Method for quantification of AmB
For quantification of AmB in the in vivo samples, a Waters Xevo TQ-S triple quadrupole tandem
mass spectrometer with an electrospray ionization source, equipped with the ACQUITY UPLC®
I-Class System was used (Waters Corporation, Milford, MA, USA). Data acquisition was
performed with Waters Xevo TQ-S quantitative analysis TargetLynx® software and data
processing was executed with MassLynx® mass spectrometry software. Separation operations
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7μm
particle size). The mobile phase consisted of water (A), and acetonitrile (B) both containing 0.1 %
formic acid at a flow rate of 1.0 mL/min with a gradient elution as follows: 0 min, 98 % A/2 % B
held for 0.2 minutes and in next 2.3 min to 100% B. Each run was followed by a 1-minute wash
with 100 % B and an equilibration period of 2 minutes with 98 % A/2 % B. The column and sample
temperature were maintained at 50ºC and 10C, respectively. The effluent from the LC column
was directed into the ESI probe. Mass spectrometer conditions were optimized to obtain maximal
sensitivity. The following conditions were used for the electrospray ionization (ESI) source: source
temperature 150°C, desolvation temperature 600°C, capillary voltage 3.0 kV, cone voltage 40 V,
nebulizer pressure, 7 bar and nebulizer gas 1100 L·h−1 N2. Argon was used as the collision gas.
The collision energies were optimized and ranged from 10 to 15 eV for individual analytes.
Instrument control and data processing were performed by using MassLynx® software (version
4.1, Waters, Milford, MA, USA). Mass spectra were acquired in positive mode and multiple
reaction monitoring (MRM) mode. The multiple reaction monitoring (MRM) mode was applied
to monitor the transitions of quantifier ion to qualifier ions (the precursor to fragment ions
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transitions) of m/z 924.4  m/z 107.5, 743.2, 761.4 for AmB and m/z 666.2  m/z 467.2, 485.2,
503.2 for natamycin. Natamycin was used as the internal standard. Confirmation of compounds
was achieved through three fragment ions.
AmB was quantified - by inverse prediction of concentration from the peak area obtained for LCMS/MS—using a calibration curve (coefficient of determination r2 ≥ 0.98) determined for ocular
tissues, such as the cornea, Iris-Ciliary Bodies, Aqueous Humor, Vitreous Humor, and Sclera. The
process and extraction efficiency were greater than 90% for all the tissues.
Physicochemical characterization of NLC
Assay, drug loading, and entrapment efficiency
The drug was extracted from NLC with a 50:50 solvent mixture of DMSO and methanol. For the
total drug content, the formulation (10 µL) was diluted 100 times with the solvent mixture (990
µL), stirred vigorously, and centrifuged at 13000 rpm. The drug in the supernatant was quantified
using HPLC. Entrapment efficiency of the drug was calculated by determining the free
unentrapped drug. The formulation was filtered through the Amicon® filters (pore size of 100,000
Daltons) at 5000 rpm. The drug in the filtrate was quantified with HPLC. Percent entrapped drug
was calculated using equation 2.1, whereas, drug loading was calculated using equation 2.2.

%EE 

%DL=

Wt -Wf
.100
Wt

Wt -Wf
.100
Wl

Where, Wt = Total AmB content in the formulation
Wf = AmB in the aqueous phase
Wl = Total weight of the nanoparticles.
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(2.1)

(2.2)

Particle size, PDI, and zeta potential
Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, USA) was used to measure
mean hydrodynamic particle size (z-average), PDI, and zeta potential. The formulations were
diluted 100 times prior to measurements. All the measurements were made at 25oC.
Scanning transmission electron microscopy (STEM)
A drop (20 µL) of the optimized PEG-NLC-AmB was placed on parafilm. A 200 mesh copper
grids coated with a thin carbon film was exposed—film side down—to the drop of the PEG-NLCAmB. After 30 seconds, the grid was raised, and excess PEG-NLC-AmB was removed using a
filter paper. Immediately, the grids were placed on a drop of ultra-pure water. Further, the grid was
raised—excess water was removed—and placed on a drop of 1% uranyl acetate to stain the
nanoparticles (231). After a minute, the grid was raised dried completely and examined under a
Zeiss Auriga microscope (Carl Zeiss, New York) operating in STEM mode at 30kV.
In vitro antifungal activity
Antifungal susceptibility assay was performed as per Clinical & Laboratory Standards Institute
(CLSI) protocols (232-234). AmB formulations were tested against three pathogenic fungi:
Candida albicans (ATCC 90028), AmB resistant Candida albicans (ATCC 200955) and
Aspergillus fumigatus (ATCC 204305), following CLSI guidelines. Nanoparticle formulations
were serially diluted using assay medium (RPMI 1640, pH 7.0). Diluted samples were transferred
to 96 well assay plates (10 μL) in duplicate. Inocula was prepared by suspending growth from agar
in 0.9% saline and diluted in RPMI 1640 (pH7.0, MOPS) medium after comparison to the 0.5
McFarland standard to have a final inoculum of 1.0 x 104 CFU/ml for Candida and 2.7 X 104
CFU/mL for Aspergillus in 190 μL of the medium. The assay plates were measured at the OD530
wavelengths prior to and after incubation at 35°C for 48h. MICs, defined as the lowest test
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concentration that allows no visual growth, were calculated for all formulations. To determine
MFCs, 4 μL aliquots of cells from each well was spotted on drug-free SD agar plates and was
incubated for 24-48h. MFC is defined as the lowest test concentration that allows no detectable
growth on agar plate. All experiments were performed in triplicates.
Cytotoxicity Assay
The cytotoxicity of the selected formulations was determined against human retinal pigmented
epithelium cells - ARPE-19 (ATCC CRL-2302). The cells were seeded in 96-well plates at a
density of 10,000 cells/well. After an incubation of 24 hrs, formulation samples at various dilutions
were added and the cells were further incubated for 48 hrs. Cellular viability was determined by
using a tetrazolium dye (WST-8), which is converted to a water-soluble formazan product in
presence of 1- methoxy PMS by the activity of cellular dehydrogenases. The color of formazan
product was measured by reading the absorbance at 450 nm. Percent decrease in cell viability of
formulation treated cells was calculated in comparison to the vehicle treated cells. Doxorubicin
and benzalkonium chloride were included as the positive controls for cytotoxicity towards the
selected cell lines.
In vitro transcorneal permeability
Freshly excised whole eye globe stored in Hank’s balanced salt solution (HBSS) solution on ice
was shipped overnight from Pel-Freez® Biologicals. Upon receipt, corneas were separated and
washed with phosphate buffer saline (PBS, pH 7.4) and mounted for transcorneal studies on
modified Franz diffusion cells (PermeGear® Inc., Cranford, NJ) with a spherical joint (235-237).
The water jacket around the cells maintained a constant temperature (34 ± 0.2°C, simulated
average ocular surface temperature). The receptor chamber was filled with 2.5 % randomly
methylated cyclodextrin mixed with Dulbecco’s phosphate-buffered saline (DPBS) and the donor
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was filled (1 mL) with 0.3 % w/v AmB formulations—AmB-NLC and AmBisome® (control)—
diluted using sterile water for infection, respectively. PEGylated NLC and AmBisome® were
evaluated for transcorneal permeation. The aliquots of 300 µl were drawn and replaced with the
donor solution and aliquots were analyzed for AmB using HPLC. The weight of the corneas was
recorded before and after the experiment to evaluate corneal hydration, indicating corneal
integrity. Further, the corneas were homogenized; the drug was extracted from the cornea and
analyzed using HPLC.
In vivo ocular bio-distribution studies
In vivo, ocular biodistribution of AmB was studied in 8 male New Zealand albino rabbits (weighing
around 2 - 2.5 kg), procured from Harlan Labs (Indianapolis, IN, USA). All animal studies
conformed to the tenets of the Association for Research in Vision and Ophthalmology statement
on the use of animals in ophthalmic vision and research and the University of Mississippi
Institutional Animal Care and Use Committee approved protocols. Rabbits were anesthetized
using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg), injected intramuscularly.
The AmB formulations, PEG-NLC-AmB, and AmBisome® (marketed AmB liposomes), were
evaluated in vivo in conscious rabbits (n=4). Six doses of each formulation were administered
(50 μL each) 60 min apart. One-hour post-instillation of the final dose, the rabbits were euthanized
with an overdose of pentobarbital injected through a marginal ear vein. The eyes were washed
thoroughly with ice-cold phosphate-buffered saline and enucleated. All the ocular tissues were
separated and homogenized; The drug was extracted from the tissues using an ice-cold solvent
mixture (9:1- methanol: DMSO) and analyzed for AmB content according to the procedure
described in Section 2.6.
Fourier transform infrared (FTIR) spectroscopy and powder X-ray diffraction
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The infrared spectra (IR) of AmB-NLC, blank PEGylated NLC and all its excipients were obtained
using Cary 660 series FTIR (Agilent Technologies) and MIRacle ATR (attenuated total
reflectance) systems. The ratios of AmB and lipids used in this set of studies were similar to the
weight ratios in the PEG-NLC-AmB.
A qualitative PXRD was done to examine the physical state of amphotericin B in PEG-NLC-AmB.
The X-ray powder diffraction patterns of the samples were recorded with the Rigaku Ultima IV
X-ray diffractometer using Ni-filtered, CuKα radiation generated at 40 kV, and a current intensity
of 44 mA. The instrument was operated over a diffraction angle (2θ) ranging from 5° to 50°.
Stability of the NLC
Optimized PEG-NLC-AmB were autoclaved (AMSCO® Scientific Model SI-120) in the
scintillation vials, at 121°C for 15 min under 15 psi pressure. The autoclaved samples were
gradually cooled to room temperature and formulations were evaluated for its physicochemical
characteristics (Section 2.7). The non-sterile formulations (stored at 4 and 25oC) were controls for
the sterile formulations. The optimized PEGylated NLC was evaluated for its stability upon
storage for a duration of 8 weeks at 25°C/75% RH and 4°C. The physicochemical evaluations were
performed as mentioned earlier in this chapter.
Statistical analysis
Analysis of variance (ANOVA) was used to analyze data from the experimental design. At p<0.05,
the differences in data were considered statistically significant. The interaction, simple-effects, and
plots for the experimental design were obtained using the R project for statistical computing
version 3.4.4.

Results and discussions
Development of PEG-NLC-AmB
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The objective of this study was to formulate and optimize PEG-NLC-AmB (Amphotericin B
loaded PEGylated nanostructured lipid particles) for ocular drug delivery. Lipid screening is a
crucial step to select the lipids with the highest drug solubility and/ or dispersibility. AmB had
higher solubility at elevated temperature in PrecirolTM ATO 5 in comparison with the other lipids
(Table 10). Castor oil was selected as the liquid lipid, due to its ability to best disperse/solubilize
AmB in comparison with other liquid lipids (Table 10).
Table 10: Lipid screening.
Liquid Lipid Solubility/Dispersion

Solid Lipid

Solubility/Dispersion

Labrafilm
Compritol
Maisine
Precirol
(+)
Capryol
GMS
Olive Oil
Dynasan 114
Sesame Oil
Dynasan 116
Soy bean oil
Gelucire 43/01
Captex 200
Gelucire 44/14
Captex 355
Gelucire 50/13
Oleic acid
Castor Oil
+
*+: Soluble/dispersed, (+): Drug aggregated upon cooling, -: Drug remain aggregated

From DSPE-PEG screening experiment, it was observed that molecular weight of PEG in mPEGDSPE played a key role in entrapping AmB and preventing its leaching from NLC (Figure 6).
Surprising results were observed; PEGylation (DSPE-PEG-2000-1.5% w/v) not only enhanced
physical stability of the NLCs, but also enhanced amphotericin B loading and prevented its
leaching over time (Figures 7,8,9, 10, and 11). In addition to DSPE-PEG-2K, other DSPE-PEGs
of varying molecular weight (1K, 5K, 10K, 20K) were tested for their ability to enhance drug
loading. The formulations using DSPE-PEG-10K and DSPE-PEG-20K were physically unstable
and lipid aggregates were observed. NLC with DSPE-PEG-5K had black residues at the bottom of

62

the vials, these indicated some type of chemical instability (either drug or lipid or DSPE-PEG-2K
degradation).

Figure 6:Precipitation of drug over the time: a)1-day, b) 8-days. Vials to the left:
PEGylated NLC, vial to the right: NLC.
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Figure 7: Visual observation of Amphotericin B loaded PEGylated NLC with various PEG
mol. wt. from left to right: 1K, 2K, 5K, 10K, 20K. First row represents day 1 and second row
represents day 30.
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Figure 8: Effect of autoclave on Particle Size and its 8-day stability.
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Figure 9: Effect of autoclave on PDI and its 8-day stability.
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Figure 11: Effect of autoclave on assay (percent drug content) and its 8-day stability.
We observed that amphotericin B is chemically stable on autoclaving but the NLCs in the colloidal
dispersion were physically unstable (statistically significant increase in particle size and PDI) at
amphotericin B loads of 0.05 % w/v and higher. This might be due to absence of bulky PEG corona
surrounding NLC that protects and stabilizes them by steric hindrance (225). The drug precipitated
out and formed a cake (not easily dispersed upon shaking) at the bottom.
The formulations (colloidal dispersion) prepared with DSPE-PEG-1K was physically stable for 8
days, both pre- and post- autoclave. There was a decrease in amphotericin B content (statistically
significant). Some precipitation was seen with the naked eyes (relatively more than 2K, but less
than 5K) at the bottom of the vials but was redispersible. Note that a 7-14-day stability post
reconstitution would be a significant advantage over what is currently available. Both pre- and
post- autoclave formulations (colloidal dispersion) prepared with DSPE-PEG-2K were stable for
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8 days. There was some precipitation seen at the bottom of the vials but was easily and completely
redispersible. This precipitate might be larger lipid nanoparticles (PDI ~0.3-0.35). DSPE-PEG5K: There was statically significant increase in PDI post-autoclave, however the remaining
formulation characteristics remained the same. DSPE-PEG-10K and DSPE-PEG-20K: There
was significant drop in assay post-autoclave and the formulations were not physically stable. The
post-autoclaved samples crystallized and froze at 4oC. The formulations,1K, 2K, 5K, were slightly
orangish upon autoclaving. There was black residue seen in formulations which had DSPE-PEG
(5K, 10K, and 20K). Over one-month there are large particles observed in formulations containing
DSPE-PEG-10K and -20K (Table 11).
Table 11: Visual inspection on day 1 and day 8 for amphotericin B loaded NLC (PEGylated and
Un-PEGylated). mPEG-DSPE was used with varying PEG molecular weight—1K, 2K, 5K, 10K,
20K.
Visual
Inspection
Black
Precipitation

Redispersibility
of settled
nanoparticles/
sedimented
lipid

Aggregation/
Creaming

Dur
atio
n
Initi
al
time
Day
8

UnPEGylated
NLC
No ppt

DSPE-PEG1K
No ppt.

No ppt

No ppt

No ppt

some ppt.

Moderate
ppt.

Extreme
ppt.

1
Mon
th
Day
8

No ppt

No ppt

No ppt

some ppt.

Extreme
ppt.

Extreme
ppt.

Easily
redispersible
(2-4 sec)

Easily
redispersible
(2-4 sec)

Easily
redispersible
(2-4 sec)

Redispersi
ble (10-15
sec)

Redispersi
ble (10-15
sec)

Redispersible
(10-15 sec)

Easily
redispersible
(2-4 sec)
No
aggregation

Easily
redispersible
(2-4 sec)
No
aggregation

Easily
redispersible
(2-4 sec)
No
aggregation

No
aggregatio
n
No
aggregatio
n

Not easily
redispersib
le
Particle
aggregatio
n

Not easily
redispersible
Particle
aggregation

1
Mon
th
1
Mon
th

PEGylated NLC
DSPE-PEGDSPEDSPE2K
PEG-5K
PEG-10K
No ppt.
No ppt.
Some ppt.
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DSPEPEG-20K
Moderate
ppt.

To further understand this effect, mPEG-2000-DSPE concentration was varied at 3 levels as a part
of the design of experiments. The amount of castor oil, AmB, and number of HPH cycles were
also varied in the experimental design to maximize entrapment and drug loading.
Optimization of the PEGylated NLC
The PEG-NLC-AmB was optimized using Box-Behnken design (Table 12). The formulation was
optimized to study the effect of PEGylation (amount of mPEG-2000-DSPE) on drug loading,
stability, and various physicochemical characteristics of the formulation. Several factors (based on
preliminary trial) were noted, which causes variation in the formulation characteristics, to choose
the factor relevant to our hypothesis. Surfactant type and concentration cause variation in particle
size and PDI by moderating interfacial tension (238). Unless surfactant has an effect on the lipid
phase, it does not cause increase in drug loading, however, it can lead to reduced entrapment
efficiency by increasing solubility of the drug in the aqueous phase (micelles) (221, 239).
Moreover, particle size, PDI, entrapment efficiency, and drug loading are affected by the type and
concentration of solid and liquid lipid (240). The non-toxic concentration of the surfactants was
used (241). The in vitro and in vivo histology was performed for current optimized formulations
to evaluate the safety of PEG-NLC-AmB. Additionally, optimized formulation was evaluated for
in vitro cytotoxicity and anti-fungal activity.
Table 12: Model summaries.
Parameters

Entrapment efficiency (Y3)
Drug Loading (Y4)
Coefficient
p-value Coefficient
p-value
2.82
Intercept
98.43
X1 (DSPE-PEG)
5.62
0.085
-0.32
<0.0001*
X2 (Amphotericin B)
1.64
<0.0001*
X3 (No. of cycle of HPH)
7.98
0.018*
X4 (Castor oil)
-0.03
0.887
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X1X2
X1X3
X12
X42
R2
Adj. R2
F value
Model p-value

-11.84
0.41
0.33
4.88 (df=3,1)
0.009*

0.039*
-

-0.53
0.5
0.36
0.94
0.91
43.49 (df=6,1)
< 0.0001*

<0.05
0.005
0.0323
-

*p-value<0.05

The two major challenges in formulating the PEG-NLC-AmB are: the drug solubility/
dispersibility in lipid and leaching out of the drug. mPEG-2000-DSPE or Cremophor® EL
increased drug loading, however, Cremophor® EL failed to prevent drug leaching.
y  0  1 x1  2 x2  3 x3  4 x4  5 x1 x2  6 x1 x3  7 x1x4  8 x2 x3  9 x2 x4  10 x3 x4  11x12  12 x22  13 x32  14 x42

(2.3)

Twenty-five formulations were prepared using the Box-Behnken design. Particle size, zeta
potential, polydispersity index, entrapment efficiency, and drug loading were the responses (Table
12). ANOVA was applied to fit the model and understand the effect of predictors on responses
(equation 2.3). The significant model terms were selected by an automated stepwise procedure
(Table 12). The linear, two-factor interaction and the quadratic models were compared using the
goodness-of-fit, analysis of variance and adjusted r2 in Design Expert version 8 (2.3). The positive
unstandardized coefficients (β) represent an increase in response variable with a unit increase in
the factor considering all the other factor in the equation constant (2.3); The reverse applies to the
negative coefficients—unless there exist an significant statistical interaction (242). A significant
interaction (product of two factors) implies that the effect of a factor is moderated by other factor
(243), which signifies that effect of a factor on response variable is different at different levels of
moderator (another interacting factor). The intercept of the model is average response. The model
was considered statistically significant, when the F-value is higher than Fcrictical (at p<0.05), which
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validates existence of a linear relationship between the predictors and the response variable,
however, adjusted r2 evince strength of this relationship (Table 12).
Particle size, polydispersity index, and zeta potential
The mean particle size for the experimental runs was 275 nm, the polydispersity index was 0.35,
and zeta potential was -52.5 mV. The model for particle size, PDI, and zeta potential was not a
good fit. Therefore, the effect of all the factors on variation in particle size, PDI, and zeta potential
was statistically insignificant. The variation observed in these parameters might be due to a
confounding factor, such as the temperature of the solution during homogenization or errors
(instrumental and/ or manual). Therefore, the formulation is robust for particle size, PDI, and zeta
potential at various levels of the factors (concentration of AmB, mPEG-2000-DSPE, and castor
oil). The variations in data can further be reduced by stringent and uniform manufacturing
conditions. There were few responses with higher particle size and PDI, therefore we need to
perform more experiments with true replicates to understand these outliers.
Entrapment efficiency
Entrapment Efficiency (%)  98.43  5.62 * x1  7.98* x3 -11.84 * x1 * x3 (2.4)

The mean percent entrapment efficiency was 98.43 % (w/w). Amount of mPEG-2000-DSPE and
no. of cycles of HPH are represented as x1 and x3 respectively in the equation. There exists a
significant interaction (F (1,1) = 4.28, p-value-00395) between the amount of mPEG-2000-DSPE
and no. of cycles of HPH. Therefore, the effect of mPEG-2000-DSPE on entrapment efficiency
changes when no. of cycles of HPH changes. Increase in mPEG-2000-DSPE concentration
increases entrapment efficiency when the formulation was homogenized for 10 HPH cycles,
however, this effect is absent when the formulation was homogenized for 30 mins (Figure 12).
This interesting effect of DSPE-PEG-2K may be due to interaction (physical and chemical) with
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AmB. Additionally, nature of DSPE-PEG-2K interaction with AmB needs to be studied. No. of
HPH cycles caused increased AmB loading, which may be due to increased particle-particles
collision and stabilization of nanoparticles.

71

Figure 12: Contour plot and 3-D surface plot illustrating the interaction between
amphotericin B and DSPE-PEG-2000.
Drug loading

Drug Loading (%)  2.82 - 0.32* x1  1.64* x2 - 0.53* x1  x2  0.5x12  0.36x22

(2.5)

The mean drug loading was 2.82 % (w/w). Drug loading was significantly affected by the
concentration of mPEG-2000-DSPE, AmB. From the experiments (Figure 13), we observed
amount of AmB had a positive effect on the drug load. The effect of castor oil was not statistically
significant on the drug loading. At 0.1% AmB, increase in mPEG-2000-DSPE lead to increase in
drug loading, however, at 0.3 % (w/w), increase in mPEG-2000-DSPE lead to reduced drug
loading. From the preliminary trials, it was also seen that mPEG-2000-DSPE is essential for
loading AmB, therefore, it cannot be eliminated from the lipid phase.
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Figure 13: 3-D surface plot and contour plot illustrating interaction between amphotericin B
concentration and DSPE-PEG-2000.
Optimization
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The constraints (desired responses) were added in the Design Expert® version 8 to obtain
optimized values of the predictors. The constraints were maximum entrapment efficiency and drug
loading. The optimized independent variables are presented in Table 13 with the desirability of
0.9. The particle size and PDI for the optimized formulation were found to be 218 ± 5 nm and 0.3
± 0.02. The particle size of the PEG-NLC-AmB were confirmed by STEM imaging (Figure 14).
The drug loading for the optimized PEG-NLC-AmB was found to be 4.6 ± 0.1 % (w/w) and the
entrapment efficiency was found to be 92.7 ± 2.5 % (w/w).
Table 13: Optimized value of the predictor variables.

Variables

Optimized value (%)

DSPE-PEG-2K

0.75

Amphotericin B

0.3

Castor Oil

2

No. of cycles if HPH

30
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Figure 14: STEM image of the optimized formulation.
FTIR And PXRD analysis
From the FTIR analysis, no conclusive results were obtained. The PEG-NLC-AmB, as well as a
physical mixture containing AmB, lacked characteristic peaks of AmB, which can be attributed to
insensitivity of the instrument to extremely low concentrations of AmB. However, powder X-ray
diffraction—provides a unique fingerprint for crystalline substance—was performed to obtain
decisive results. The unique peaks for AmB were 13.96, 15.1, 17.17, 18.26, however, none of these
peaks were present in the PXRD spectra of PEG-NLC-AmB (Figure 15). Therefore, we can
conclude that AmB was not crystalline, and entrapped in the nanoparticles.
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Figure 15: P-XRD spectra for blank NLC, amphotericin B NLC, and amphotericin B.
Stability of the NLC
Particle size, PDI, and drug content were analyzed to evaluate the physical and chemical stability
of the formulation. Alteration in particle size and PDI are significant indicators of physical stability
(244). Some AmB (1-2 %) stays unentrapped and settles out within 24 h. The optimized
formulation was stable for 1 months at both 4 oC and 25 oC (Figure 16), ascribed to electrostatic
and stearic stabilization. The surface charge (-50 to -55 mV) on PEG-NLC-AmB causes
electrostatic repulsion between particle, thereby preventing aggregation of nanoparticles. In
addition to the surface charge, bulky corona of the PEG on the surface of the nanoparticles causes
stearic stabilization.
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Figure 16: Evaluate PDI (a), entrapment efficiency (b), and particle size (c) for stability at
4oC and 25oC and post-autoclave.
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The autoclaved PEG-NLC-AmB were stable with insignificant differences in particle size and
entrapment efficiency. However, a significant reduction (p < 0.05) in PDI was observed post
autoclave (Figure 16). However, this could be due fluidity of NLC at elevated temperature, leading
to collision and breaking of larger nanoparticles, causing narrow PDI. It is known that autoclaving
can further enhance the stability of the nanoparticles, due to the formation of lipid bilayer around
the particles (245-248).
In vitro fungicidal activity
A microdilution experiment was performed in wild type (WT) Candida albicans (ATCC90028),
AmB resistant Candida albicans (ATCC 200955) and Aspergillus fumigatus (ATCC 204305) as
per Clinical & Laboratory Standards Institute (CLSI) protocols 41-43. PEG-NLC-AmB, NLCAmB, AmB pure compound (AmB) and commercially available AmB formulations Fungizone
and AmBisome were tested. Recovery assay was performed for fungicidal activity at both day 1
and day 10 post preparation. At day 1 in Candida, PEG-NLC-AmB showed the strongest
antifungal activity among AmB, Fungizone and AmBisome (Fig. 17 A & Table 14). The recovery
assay also established lowest minimum fungicidal concentration (MFC) value for PEG-NLC-AmB
i.e. 0.16 μg/mL. Against Aspergillus, PEG-NLC-AmB showed lower MIC value (1.25 μg/ml)
compared to AmB (2.5 μg/ml) and was comparable to AmBisome (1.25 μg/ml). MIC with
Fungizone was 0.62 μg/ml (Table 14).
At day 10 post formulation, autoclaved PEG-NLC-AmB (PA-PEG-NLC-AmB) was also included
in the matrix and fungicidal assay was performed in both WT and AmB resistant Candida strain.
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Figure 17: Antifungal activity of AmB formulations. Left panel shows Java Tree visualization
of microdilution assay data. Right panel shows cell recovery on drug-free agar plates. Each
formulation was tested at 5.0-0.01µg/ml with 2-fold dilutions. Color bar represents relative
growth. A. Antifungal activity on Day 1 post AmB formulation in WT Candida. B. & C.
Antifungal activity on Day 10 post AmB formulation in WT and AmB resistant Candida
strains, respectively. Each experiment was performed in triplicates. Here, PEG-NLC-AmB
represent PEG2K-NLC-AmB.
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Table 14: Summary of Antifungal profile of formulations.
AmB-resistant
Candida albicans (WT) Candida
(ATCC 90028)
albicans (ATCC
200955)
MIC
MFC
(µg/mL)
(µg/mL)
MIC
MFC
(Day 1/
(Day 1/
(µg/mL) (µg/mL)
Formulations
Day10)
Day10)
(Day10) (Day10)
0.08/0.31
0.16/0.31
1.25
1.25
PEG2K-NLC-AMB
NA/NA
NA/NA
NA
NA
PEG2K-NLC
0.16/0.62
0.16/2.5
NA
NA
AmB-NLC
NA/NA
NA/NA
NA
NA
NLC
ND/0.31
1.25
2.5
PA-PEG2K-NLC-AmB ND/0.16
0.62/0.62
1.25/1.25
2.5
2.5
AmB
0.31/0.62
0.31/0.63
1.25
1.25
Fungizone®
0.62/1.25
0.62/1.25
NA
NA
AmBisome®

Aspergillus
fumigatus
(ATCC 204305)

MIC (µg/mL)
(Day 1)
1.25
NA
1.25
NA
ND
2.5
0.62
1.25

*ND - Not Done, NA - Not Achieved
In vitro cytotoxicity evaluation
The placebo (no AmB) formulations PEGNLC and NLC alone were tested for cytotoxicity towards
the retinal pigmented epithelial cells (ATCC ARPE-19) in a concentration range of 0.03% - 1%.
PEGNLC and NLC did not show any toxicity up to a highest concentration of 1%. The drug
formulations PEG-NLC-AmB, NLC-AmB, AmB, PA-PEG-NLC-AmB, Fungizone and
AmBisome were tested in the concentration range of 0.95 – 30 μg/mL. They were not cytotoxic to
ARPE-19 cells up to a highest concentration of 30 μg/mL, indicating a high therapeutic index. The
control drug benzalkonium chloride was toxic with an IC50 of 3.9 μg/mL.
Amphotericin B loaded SLNs have been evaluated by several research groups. Patel and Patravale
prepared Amphotericin B loaded SLNs (amphotericin B load: 12.5 – 37.5 % w/w of lipid) for oral
bioavailability evaluation (249-251); Butani, Yewale and Misra tested the utility of Amphotericin
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B loaded SLNs (amphotericin B load: 7.4 – 11.4 % w/w of lipid) for topical application (252). The
formulations demonstrated better permeability compared to Amphotericin B dispersion, 2-fold
greater in vitro activity against

Trichophyton rubrum fungal species and the freeze dried

formulations demonstrated 3M stability (250); Chaudhari, Desai, Patel and Patravale prepared
Amphotericin B SLNs (amphotericin B load: 12.5 – 37.5 % w/w of lipid) that had lower toxicity
but had a higher MIC which was explained to be because of sustained release of Amphotericin B
from the SLNs (250-253); Garse, Jagtap and Kadam prepared Bifonazole loaded SLNs which
were loaded in gels for topical application (254).
Tripathi et al. (255) prepared NLCs of amphotericin B (amphotericin B load 0.01 % w/v of total
formulation i.e. colloidal dispersion; 9 % w/w of lipid content) to increase therapeutic efficacy and
reduce toxicity. The authors suggested that it would be preferable to deliver amphotericin B
through NLCs. However, these formulations were very different from the present invention.
Firstly, the formulations used organic solvents. Secondly the NLCs were not PEGylated.
Importantly, the authors did not present any data on the stability of the NLCs in a colloidal
dispersion state or autoclavability. Most importantly, the importance of the molecular weight of
the PEG on the physical stability of the NLCs has not been identified, which makes this report
unique. Fu et al. (256) prepared AmB loaded NLCs that had been surface modified with chitosan
and evaluated these particles for ocular delivery. However, the formulations were not PEGylated
nanoparticles. The authors did not study stability of the amphotericin B and also fails to mention
amphotericin B load.
In another study, DSPE-PEG 2000 was used to prepare PEGylated lipid nanoparticles (0.7 % w/v
amphotericin B of total formulation). Although the authors call these PEGylated lipid
nanoparticles the formulations appear to be liposomes, which is distinctly different from the NLCs
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described in the present disclosure. Moreover, this article does not disclose the critical importance
of the PEG molecular weight on the drug loading, physical and chemical stability of the
nanoparticles in a colloidal dispersion or the effect of autoclaving on the physicochemical
characteristics of the amphotericin B loaded lipid nanoparticles (257).
In vitro and In vivo evaluation
AmB was not detected in the receptor chamber in an in vitro transcorneal study, for both
AmBisome® and PEG-NLC-AmB. Therefore, the drug is delivered to the cornea at same rate from
both the AmB formulations. Due to slow flux across cornea, AmB was not detected in the receptor
media in 3 hours (258). The study cannot be extended beyond 3 hours as the corneal integrity
would be lost.
Damaged epithelium causes the uncontrolled amount of water to reach stroma, causing swelling
of proteoglycans (25, 259). The percent corneal hydration in the range of 76 to 83 % indicates that
corneal integrity was intact (260). In the current study, percent hydration (78.8 ± 2.51 % w/w) was
in the above-mentioned range, therefore, we can conclude that the cornea did not lose integrity
upon contact with an AmB loaded formulation for 3 hours. PEG-NLC-AmB were studied in vivo
in Albino New Zealand rabbits. The dosing frequency (50 µL every 60 min.) simulated the
frequency in a severe ocular fungal infection. Amphotericin B was detected in all the tissues for
PEG-NLC-AmB and AmBisome® (Figure 18). This is the first study that evaluates and compares
in vivo ocular biodistribution of PEG-NLC-AmB with marketed preparation. A few reports have
formulated amphotericin B loaded formulation for ocular drug delivery. The studies have reported
in vitro antifungal activity of the formulations. However, none of the reports talk about the
formulations efficacy in delivering drug to various ocular tissues, neither in vitro nor in vivo. The
studies were performed on healthy eye; however, an infected eye has damaged epithelium and
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therefore, amphotericin B permeation would be much higher. It has been observed that
amphotericin B marketed preparations are able to cure upon repeated administration. The major
disadvantage of marketed preparations is that once they are reconstituted, exceptional care has to
be taken in order to prevent any precipitation and bacterial contamination. According to the label
of the marketed preparations, they must be used within 24 hours post-reconstitution and stored at
4oC protected from light. However, the formulation we propose is autoclavable, and stable up to
one-month.
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Figure 18: Concentration (ug/g) of amphotericin B in various ocular tissues (aqueous humor,
cornea, iris-ciliary body, sclera, and vitreous humor (+/- 1 Standard Error). The
concentration for Marketed preparation and PEGylated NLC for all the tissues were not
statistically significant (p<0.05).
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Conclusion
The quality-based design approach was used to optimize PEG-NLC-AmB. The optimized
PEGylated NLC with small particle size, narrow PDI were formulated, which were stable for the
at least one-month duration. This study is the first report—to author’s knowledge—comparing the
ocular distribution of PEG-NLC-AmB and AmBisome® (marketed amphotericin B liposome).
Additionally, the unique effect of mPEG-2000-DSPE to enhance amphotericin B loading and
prevent drug leaching has not been reported before. Further investigations are needed to
understand the mechanism by which mPEG-2000-DSPE has effect on amphotericin B loading
efficiency. A critical finding of these report is that the innovative PEG2K-NLC-AmB had
significantly enhanced anti-fgunal activity against wildtype and resistant species in comparison to
the marketed preparation. The study also reports PEG-NLC-AmB whose ocular bio-distribution is
statistically insignificant in comparison to the marketed liposomal preparation. The PEGylated
NLC were prepared using a solvent-free processing and high-pressure homogenizer (ease of scaleup), making it potential economic alternative for AmBisome® for ocular drug delivery of
amphotericin B. In addition, the PEGylated NLC also form the base, which on further surface
engineering, potentially could form NLC with superior in vivo characteristics in comparison with
marketed liposome for ocular drug delivery. However, the comparison of amphotericin B NLC
and AmBisome® needs to be performed on animal model induced with ocular infection.
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CHAPTER III
Strategies to Prolong Amphotericin B’s Precorneal Residence—Pegylated
Lipid Nanoparticles Entrapped in the Ion-Sensitive Hydrogel and
Chitosan-Coated Pegylated Lipid Nanoparticles
Introduction
In previous chapter, we reported formulation, optimization, and stabilization of
amphotericin B loaded-PEGylated (2K) nanostructured lipid carriers (PEG2K-NLC-AmB). We
observed that PEGylation enhanced stability of the amphotericin B in the nanoparticles and
reduced leaching of drug over time. PEGylated nanostructured lipid carriers were physically and
chemically stable for over the month and retained its stability upon autoclaving. From the
biodistribution studies we observed that amphotericin B from lipid nanoparticles permeated
through the scleral pathway (AmBisome® and nanostructured lipid carriers). Form literature it
was known that amphotericin B deoxy cholate (Fungizone®) led to permeation of amphotericin B
though corneal pathway as sodium deoxycholate is known to cause opening of tight junctions. In
addition, it is known that sodium deoxy cholate, a major constituent of Fungizone® (marketed
amphotericin B product), a permeation enhancer, can cause adverse effects on cornea upon
repeated exposure (211). These formulations are administered primarily as eye drops in case of
severe fungal infections and known to be short-lived in precorneal region due to precorneal
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drainage. In case when product is ineffective in curing an ocular fungal disease,
ophthalmologist choose to administer formulation either as intravitreal injection or via parenteral
route, which are known to cause poor patient compliance. Systemic administration of amphotericin
B needs close monitoring to prevent systemic adverse effects. This creates a need for developing
formulation that can be administered as topical drops and also have prolonged precorneal
residence.
No enhancement in permeability was observed from in vivo biodistribution studies for
amphotericin B loaded PEGylated nanostructured lipid carrier in comparison to AmBisome®,
which can be attributed to slow permeation of amphotericin B and faster precorneal drainage. In
order to prolong precorneal residence time, we employed and compared two strategies: 1. Chitosan
coated PEGylated nanostructured lipid carriers, 2. Entrapment of PEGylated nanostructured lipid
carriers in in situ gelling system. Therefore, the primary aim was to study the effect of transforming
the surface of PEG-NLC-AmB mucoadhesive (by using chitosan) and entrapping PEG-NLC-AmB
in in situ gelling systems on precorneal residence and in vivo biodistribution. In earlier chapter we
observed that PEG-NLC-AmB were stable upon autoclaving. These formulations will be dosed
multiple times due to chronic nature of the fungal infection and hence, require certain preservative
to keep formulation sterile. Marketed preparation is incompatible with preservative due to chargecharge interaction; therefore, our secondary aim was to study effect of preservative (Benzalkoium
chloride) on the stability of the formulations.

Materials and methods
Materials
AmB was purchased from Cayman Chemicals Pvt. Ltd. (Michigan, US). PrecirolTM ATO 5 was a
gift samples from Gattefossé (Weil and Rhein, Germany). DSPE-PEG-2K-(N-(Carbonyl-
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methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine

(mPEG-

2000-DSPE) was obtained from Lipoid GmbH (Germany). mPEG-DSPE were obtained from
Creative PEGWorks® (Chapel Hill, NC, USA). Surfactants, Benzalkonium chloride, castor oil,
xanthan gum, gellan gum, and analytical grade solvents were procured from Fisher scientific
(Massachusetts, US). Chitosan chloride (Protasan®) was obtained from FMC biochemicals
(Norway). Whole eyes of male albino New Zealand rabbits for the transcorneal study were
procured from Pel-Freez® Biologicals (Rogers, AR, USA).
Fabrication of chitosan coated- and gel entrapped PEGylated and Non-PEGylated NLC
AmB-NLC were prepared using the formula in Table 15 and following procedure described in
CHAPTER II. To prepare chitosan coated PEG-NLC-AmB system (Chi-PEG2K-NLC-AmB),
chitosan was added to PEG-NLC-AmB and stirred for 10 mins at 2000 rpm (Table 13).
Concentration of chitosan was selected as per earlier report from Dr. Majumdar’s lab (261).
To prepare PEG-NLC-AmB entrapped in in situ gelling systems (PEG-NLC-AmB-Gel), small
modification in the procedure was required. The lipid phase along with AmB was heated to 75oC
and a coarse emulsion was formed by dropwise addition of the aqueous phase to the lipid phase
under magnetic stirring at 2000 rpm. Further, the ULTRA-TURRAX® T 25(IKA works INC., NC,
USA) was used to homogenize the coarse emulsion into a fine emulsion at 16000 rpm
(temperature: 60o C). This fine emulsion was homogenized (temperature: 50o C) at 1500 bars for
5-15 mins in high-pressure homogenization (HPH) (Emulsiflex C5-Avestin, Canada). To this
emulsion gellan gum and xanthan gum were added and homogenized with ULTRATURRAXTM
for 2 mins at 16000 rpm. Effect of concentration of gellan gum (0.1-0.5 % w/v) and xanthan gum
(0.1-0.3% w/v) on physicochemical characteristics—particle size, polydispersity index (PDI), zeta
potential (ZP), gelling time, firmness, viscosity, entrapment efficiency, drug loading, and total
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drug content—were studied to obtain an optimized formulation (Table 16).

Table 15: Chitosan coated- and gel entrapped PEGylated and Non-PEGylated NLC.

Components
PrecirolTM
ATO 5
Castor Oil
mPEG(2K)DSPE. Na salt
Cremophor®
EL
Amphotericin
B

UnPEGylated
NLC
(%w/v)

PEG2K-NLC-AmB
Chitosan PEG2K(%w/v)
NLC-AmB (%w/v)
Lipid Phase

PEG2K-NLC-AmB
Gels (%w/v)

3
1.5

3
2

3
2

3
2

0

0.75

0.75

0.75

1.5

0

0

0

0.1

0.3

0.3

0.3

Aqueous phase
Tween 80
Poloxamer
188
Glycerin
Water
Xanthan gum
Gellan gum
Chitosan
(Added after
nanoparticles
are formed)

0.8

0.8

0.8

0.8

0.3
2.5
QS
NA
NA

0.3
2.5
QS
NA
NA

0.3
2.5
QS
NA
NA

0.3
2.5
QS
0.1-0.3
0.1-0.5

NA

NA

0.1

NA

Table 16: Formulation run with variable xanthan and gellan gum to select optimized in situ
gelling agent.

Run
1
2

Factor 1
A: Xanthan
Gum/10 mL
mg
10
20
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Factor 2
B: Gellan Gum
mg/10 mL
mg
50
30

3
4
5
6
7
8
9

10
30
10
20
30
30
20

10
10
30
50
30
50
10

Fabrication of Formulation with Benzalkonium chloride (BAK; preservative)
To the amphotericin B formulations (AmBisome®, Fungizone®, PEG-NLC-AmB, Chi-PEGNLC-AmB, PEG-NLC-AmB-Gel) 0.05% (w/v) of weighed BAK is added and stirred for 5 mins
at 2000 rpm to ensure homogenous mixing of preservative. Changes in particle size and PDI of all
formulations were observed for 7 days.
Bioanalytical Method for quantification of AmB
For quantification of AmB in the in vivo samples, a Waters Xevo TQ-S triple quadrupole tandem
mass spectrometer with an electrospray ionization source, equipped with the ACQUITY UPLC®
I-Class System was used (Waters Corporation, Milford, MA, USA). Data acquisition was
performed with Waters Xevo TQ-S quantitative analysis TargetLynx® software and data
processing was executed with MassLynx® mass spectrometry software. Separation operations
were accomplished using a C18 column (Acquity UPLC® BEH C18 100 mm×2.1 m, 1.7μm
particle size). The mobile phase consisted of water (A), and acetonitrile (B) both containing 0.1 %
formic acid at a flow rate of 1.0 mL/min with a gradient elution as follows: 0 min, 98 % A/2 % B
held for 0.2 minutes and in next 2.3 min to 100% B. Each run was followed by a 1-minute wash
with 100 % B and an equilibration period of 2 minutes with 98 % A/2 % B. The column and sample
temperature were maintained at 50ºC and 10C, respectively. The effluent from the LC column
was directed into the ESI probe. Mass spectrometer conditions were optimized to obtain maximal
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sensitivity. The following conditions were used for the electrospray ionization (ESI) source: source
temperature 150°C, desolvation temperature 600°C, capillary voltage 3.0 kV, cone voltage 40 V,
nebulizer pressure, 7 bar and nebulizer gas 1100 L·h−1 N2. Argon was used as the collision gas.
The collision energies were optimized and ranged from 10 to 15 eV for individual analytes.
Instrument control and data processing were performed by using MassLynx® software (version
4.1, Waters, Milford, MA, USA). Mass spectra were acquired in positive mode and multiple
reaction monitoring (MRM) mode. The multiple reaction monitoring (MRM) mode was applied
to monitor the transitions of quantifier ion to qualifier ions (the precursor to fragment ions
transitions) of m/z 924.4  m/z 107.5, 743.2, 761.4 for AmB and m/z 666.2  m/z 467.2, 485.2,
503.2 for natamycin. Natamycin was used as the internal standard. Confirmation of compounds
was achieved through three fragment ions.
AmB was quantified - by inverse prediction of concentration from the peak area obtained for LCMS/MS—using a calibration curve (coefficient of determination r2 ≥ 0.98) determined for ocular
tissues, such as the cornea, Iris-Ciliary Bodies, Aqueous Humor, Vitreous Humor, and Sclera. The
process and extraction efficiency were greater than 90% for all the tissues.
Physicochemical characterization of NLC
Assay, drug loading, and entrapment efficiency
The drug was extracted from NLC with a 50:50 solvent mixture of DMSO and methanol. For the
total drug content, the formulation (10 µL) was diluted 100 times with the solvent mixture (990
µL), stirred vigorously, and centrifuged at 13000 rpm. The drug in the supernatant was quantified
using HPLC. Entrapment efficiency of the drug was calculated by determining the free
unentrapped drug. The formulation was filtered through the Amicon® filters (pore size of 100,000
Daltons) at 5000 rpm. The drug in the filtrate was quantified with HPLC. Percent entrapped drug
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was calculated using equation 2.1, whereas, drug loading was calculated using equation 2.2.

%EE 

%DL=

Wt -Wf
.100
Wt

Wt -Wf
.100
Wl

(3.1)

(3.2)

Where, Wt = Total AmB content in the formulation
Wf = AmB in the aqueous phase
Wl = Total weight of the nanoparticles.
Particle size, PDI, and zeta potential
Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, USA) was used to measure
mean hydrodynamic particle size (z-average), PDI, and zeta potential. The formulations were
diluted 100 times prior to measurements. All the measurements were made at 25oC.
Characterization of Gel
Gelling time: Nine scintillation vials were filled with simulated tear fluid (10 mL; pH 7.4) to which
500 µL of nine amphotericin B loaded PEGylated NLC entrapped in gel formulations (Table 16)
were added, respectively. The gel depot formation time and the time till drop remained intact or
drop retained its shape was recorded. The time required for the gel depot to form was determined.
Rheology: Bohlin Visco 88 viscometer (Malvern analytical, UK) was used for rheological
characterizations. It is a cup and bob type viscometer. C14 probe was used to determine rheological
behavior and viscosity of the formulations. Six hundred microliters of the sample at room
temperature was used for the rheology analyses, which was carried out in the “up & down” ramp
mode, at pre-defined multiple shear rates (ranging from 66.5-506.5 1/s). The rheology data was
analyzed using Bohlin Software (Version 6.32.1.2).
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Texture analyses (firmness and work of adhesion): Texture analyzer TZ.XT2i (Texture
Technologies Corp., USA) was used to analyze in situ gelling systems. To analyze firmness and
adhesion, a 1” diameter (TA3) acrylic (cylindrical) probe with a soft matter kit (TA-275) was
used(262). The sample of in situ gelling system was added in the soft matter cup and parameters
used for the analyzes are listed in Table 17.
Table 17: Parameters for texture analyses of gels.
Parameter
Test mode
Pre-test speed
Test speed
Post-test speed
Target mode
Distance
Trigger type
Trigger force
Temperature

Set value
Compression
0.5 mm/sec
0.5 mm/sec
0.5 mm/sec
Distance
1.0 mm
Auto (Force)
2.0 g
Room temperature

The probe (controlled by software) is lowered till contact with gel is sensed. Upon contact,
probe travels 1 mm distance at speed of 0.5 mm/s and retracts. The force required by the probe to
travel 1 mm in to the gel is recorded and processed to give firmness and work of adhesion.
In vitro antifungal activity
For Antifungal susceptibility assays AmB formulations were tested against Candida albicans
(SC5314, ATCC MYA-2876) and AmB resistant Candida albicans (ATCC 200955) following
CLSI guidelines. Seven days old, stored at 40C after preparation, nanoparticle formulations were
serially diluted using RPMI 1640, pH 7.0 medium. After dilution samples were transferred in to
96 well assay plates (10 μL) in duplicate. Inocula was prepared by suspending growth from agar
in 0.9% saline and diluted in RPMI 1640 (pH7.0, MOPS) medium after comparison to the 0.5
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McFarland standard to have a final inoculum of 1.0 x 104 CFU/ml in 190 μL of the medium. The
assay plates were measured at the OD530 wavelengths prior to and after incubation at 35°C for 48h.
MICs, defined as the lowest test concentration that allows no visual growth, were calculated for
all formulations. To determine MFCs, 4 μL aliquots of cells from each well of MIC plate was
spotted on drug-free SD agar plates and was incubated for 24-48h. MFC is defined as the lowest
test concentration that allows no detectable growth on drug free agar plate. Each experiment were
performed in triplicates.
In vivo precorneal kinetics
In vivo pre-corneal tear kinetics of the various amphotericin B formulations (PEG2K-NLC-AmB,
Chitosan PEG2K-NLC-AmB, PEG2K-NLC-AmB Gel, AmBisome®, Fungizone) was determined
in male New Zealand White Albino Rabbits, weighing 2-2.5 kg, which were procured from Charles
River Labs. All the animal studies conformed to the tenets of the Association for Research in
Vision and Ophthalmology statement on the use of animals in ophthalmic vision and research and
the University of Mississippi Institutional Animal Care and Use Committee approved protocols.
The rabbits were dosed (50 µL) with amphotericin B formulations topically. Therefore, the amount
of amphotericin B dose received by the rabbits would be 0.15 mg form all the formulations tested.
The tear samples were collected by gentle touching a pre-weighed piece of filter paper at the
corneal surface at every time point (t = 0, 0.25, 0.5, 1, 2, 4, and 6 hours). The wet weight of the
filter paper was then recorded and the difference in their dry and wet weights was used in the
determination of the amount of tear fluid that was collected, which was used in the estimation of
amphotericin B from the tear biosamples. The extraction of amphotericin B from the tear
biosamples collected on filter papers was performed by adding six hundred microliters of 50:50
mixture of ice-cold methanol and dimethyl sulfoxide, mixing thoroughly using a vortex genie
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mixer, and then centrifuging at 13,000 rpm for 15 minutes in a table-top centrifuge. The
supernatant was then collected and analyzed for amphotericin B using a validated HPLC
quantification method that has been outlined above (0073). The data was then analyzed using
PKNCA package using R to determine various PK parameters (263). Once the study was
completed, Balanced Salt Solution (BSS) was used for washing the test eyes of the rabbits during
the wash-out period.
In vivo ocular bio-distribution studies
In vivo, ocular biodistribution of AmB was studied in 24 male New Zealand albino rabbits
(weighing around 2 - 2.5 kg), procured from Harlan Labs (Indianapolis, IN, USA). All animal
studies conformed to the tenets of the Association for Research in Vision and Ophthalmology
statement on the use of animals in ophthalmic vision and research and the University of Mississippi
Institutional Animal Care and Use Committee approved protocols. Rabbits were anesthetized
using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg), injected intramuscularly.
The AmB formulations: PEG2K-NLC-AmB, chitosan PEG2K-NLC-AmB, PEG2K-NLC-AmB
and AmBisome® (marketed AmB liposomes), were evaluated in vivo in conscious rabbits (n=4).
Four doses of each formulation were administered (50 μL each) 120 min apart. Two-hour postinstillation of the final dose, the rabbits were euthanized with an overdose of pentobarbital injected
through a marginal ear vein. Two groups of 4 rabbits each were dosed thrice with chitosan PEG2KNLC-AmB and PEG2K-NLC-AmB gel (50 μL each) 180 min apart. The eyes were washed
thoroughly with ice-cold phosphate-buffered saline and enucleated. All the ocular tissues were
separated and homogenized; The drug was extracted from the tissues using an ice-cold solvent
mixture (9:1- methanol: DMSO) and analyzed for AmB content according to the procedure
described in Section 2.6.
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Stability of the NLC
Optimized PEG-NLC-AmB were autoclaved (AMSCO® Scientific Model SI-120) in the
scintillation vials, at 121°C for 15 min under 15 psi pressure. The autoclaved samples were
gradually cooled to room temperature a nd formulations were evaluated for its physicochemical
characteristics (Section 2.7). The non-sterile formulations (stored at 4 and 25oC) were controls for
the sterile formulations. The optimized PEGylated NLC was evaluated for its stability upon
storage for a duration of 8 weeks at 25°C/75% RH and 4°C. The physicochemical evaluations were
performed as mentioned earlier in this chapter.
Statistical analysis
Analysis of variance (ANOVA) was used to analyze data from the in vivo biodistribution studies.
At p<0.05, the differences in data were considered statistically significant. In case of comparison
of two groups, two-way student ‘t-test’ was utilized.

Result and Discussions
The objective of this study was to modify PEG2K-NLC-AmB to retain them in precorneal region
for extended period. This can be achieved by adopting strategies like mucoadhesion, increasing
viscosity of the formulation, formulating films, and similar dosage forms. Here, in these regards,
we have used chitosan surface modification that would make nanoparticles mucoadhesive and
compared it with nanoparticles entrapped in in situ gelling system. These ingredients used are from
natural origin and proved to be safe in concentrations used.
Fabrication of Chitosan coated PEG2K-NLC-AmB (Chi-PEG2K-NLC-AmB)
Chitosan chloride salt was dissolved in the aqueous phase and allowed to coat the surface by
electrostatic attraction (261). Concentration of chitosan (0.3 %w/v) was obtained from published
reports from Dr. Majumdar’s lab studying effect of chitosan concentration on coating of the
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nanoparticles. Physicochemical characterizations of chitosan coated vs uncoated PEG2K-NLCAmB is summarized in Table 18. Post coating with chitosan, particle size of nanoparticles was
seen to increase from 302 ± 78 to 375 ± 2.91 nm. This increase in particle size was expected as it
signs coating of chitosan on the surface of nanoparticles, which was confirmed by zeta potential.
Zeta potential post coating with chitosan increased from -60 to +25 mV. Mucous on the surface of
the eye is negatively charged and hence, positively charged nanoparticles would bind to mucous
by electrostatic attraction and thereby, reducing precorneal drainage of the nanoparticles, and
providing prolonged exposure. Another interesting observation was that entrapment efficiency
increased post-coating from 93.7 ± 7 to 102 ± 0.15 %. This was unexpected, however, a recent
report suggested that chitosan coating leads to increase entrapment efficiency of amphotericin B
in the nanostructured lipid carriers (264). However, the authors were not able to load beyond 0.1
% (w/v), which signifies that PEGylation had greater effect on enhancing entrapment efficiency
than chitosan.
Table 18: Physicochemical characterization of PEG2K-NLC-AmB, Chi-PEG2K-NLCAMB, and PEG2K-NLC-AmB.

Particle Size
Polydispersity Index
Percent Entrapment
Efficiency
Zeta Potential

Chi-PEG2K-NLCAmB
316 ± 8.77
0.35 ± 0.01
93.7 ± 7

PEG2K-NLC-AmB
375 ± 2.91
0.35 ± 0.009
102 ± 0.15

PEG2K-NLC-AMBGel
190 ± 6.2
0.25 ± 0.01
99.15 ± 1.2

+25 mV

-60 mV

-55 mV

Fabrication of PEG2K-NLC-AmB entrapped in in situ gels (PEG2K-NLC-AmB-Gel)
Increasing viscosity of the eye drops is a widely used and most effective strategy to prolong
residence time of the formulation in the cul-de-sac. However, due to high viscosity it leads to poor
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patient compliance and inaccurate dosing. Therefore, to overcome these disadvantages, we used
in situ gelling system that has solution viscosity unless it is triggered to form gel. Triggers (cations,
temperature, pH) can depend on polymer/s used. We used a combination of two natural
polylactide, One of them being gellan gum—known to form soft-gels (low-viscosity gels) when
in contact with cations (present abundantly in tears), and Other polysaccharide used was xanthan
gum which added firmness and viscosity to the gel formed, preventing disruption of gel structure
and precorneal loss on blinking. To form PEG2K-NLC-AmB-Gel, procedure was slightly
modified. This was done as incorporation of these gums after forming nanoparticles was difficult
without using high-shear ULTRATURRAXTM. Concentrations of xanthan gum and gellan gum
were varied (Table 16) to form different formulations and were tested to achieve desired
formulations.
From the gelling time and depot collapse time it was evident that 50 mg gellan gum was necessary
to instantaneously form gel depot and maintain its structure. For all the formulations with gellan
gum concentration at 10 mg, depot was not formed on contact with simulated tear fluid (STF). For
formulations with gellan gum concentration 20 mg, the depot was formed instantaneously,
however, the depot structure was lost to form threads, which existed for 2-4 hours. The results are
summarized in Table 19. Therefore, further tests were performed on formulation 1,6, and 8 to
select optimum formulation.
Table 19: Effect of concentration of xanthan gum and gellan gum on gelling time and depot
collapse time.

Run

Factor 1
Xanthan
Gum
mg/10 mL

Factor 2
Gellan
Gum
Mg/10 mL
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Gelling
Time

Depot collapse
time

1
2
3
4
5
6
7

10
20
10
30
10
20
30

50
30
10
10
30
50
30

(+)
+
(-)
(-)
+
(+)
+

>12 hours
<2 hours
NA
NA
<2 hours
>12 hours
<4 hours

8
9

30
20

50
10

(+)
(-)

>24 hours
NA

(-): does not instantaneously form a gel depot by coming in contact with STF; +: Forms
a gel depot, however, depot structure is lost in <5 mins (broken into threads); (+): forms a gel depot
spontaneously and retains its structure.
Texture analyzer was used to characterize firmness and work of adhesion for run 1,6, and 8 (Table
20). Formulation 8 had higher firmness and work of adhesion. However, difference was not huge
to select a formulation. The formulations were furthered compared on basis of viscosity (Table
20). The pre-gelling viscosity for formulation is preferred to be low as it would provide ease of
administration and accurate dosing. Therefore, formulation 1 was selected for further in vivo
evaluations. In addition, it was also observed that these formulations showed sheer-thinning and
absence of thixotropy (Figure 19). Therefore, in vivo it is expected to lose viscosity upon blinking
and form a thin layer over the cornea and retain viscosity when blinking stops. This would lead to
increase in surface area of the cornea in contact with the formulation and also maintain some
formulation as depot in the cul-de-sac.
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Figure 19: Viscosity vs shear rate plot.
Table 20: Firmness, work of adhesion, and viscosity for run 1,6, and 8.

Run
1
6
8

Xanthan Gum Gellan Gum
mg/ 10 mL
mg/10 mL
10
50
20
50
30
50

Firmness
(g)
5.01
5.76
6.89

Viscosity
(cPs) at 15 s-1
502.77
569.36
776.55

Work of
Adhesion (g.sec)
22.57
23.52
25.55

Physicochemical characterizations of PEG2K-NLC-AmB and selected PEG2K-NLC-AmB-Gel is
summarized in Table 18. We see significant reduction in the particle size and PDI. This is due to
two possible reasons; 1. Modified method had ULTRATURRAXTM at the end which led to further
reduction I the particle size, 2. These gum increase viscosity of the external phase of the
nanoparticles, thereby, stabilizing nanoparticles immediately by reducing free/Brownian
movement and agglomeration of the nanoparticles. This also led to enhanced entrapment efficiency
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(102 ± 0.15).
Compatibility with Benzalkonium Chloride
A major drawback of the currently available amphotericin B formulations is that preservatives
cannot be added to the formulations because of stability issues. The stability of various
formulations prepared as per the invention against the marketed reconstituted solutions were
tested.
As seen in Table 7, addition of BAK to reconstituted AmBisome® or FungizoneTM led to the
formation of aggregates (7-8-fold increase in particle size and PDI 7 days after addition of BAK0.05 % w/v). On the other hand, addition of BAK to the PEG2K-NLC-AmB formulation did not
lead to any change in the physical characteristics of the formulation (particle size or PDI). The
BAK added formulations did not show any decrease in antifungal activity against Candida on Day
1; however, after 7 days a decrease in fungicidal activity was seen with the AmBisome® + BAK
and Fungizone + BAK formulations. Besides a decrease in antifungal activity, increase in particle
size could also lead to variations in ocular absorption and can also cause irritation and thus induce
lacrimation and drug loss. Addition of Chitosan or in situ gelling agents improved the physical
stability of the formulations (Table 21).
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Table 21: Effect on PS and PDI on addition of benzalkonium chloride to Amphotericin B
formulations

Stability

Before
adding
preservat
ive

Day

Physical
Stability

Day 1/Day
30

Particle
Size (nm)

Day 1
Day 30 (4
deg C)

PDI

AmB
content
(%)

Day 1
Day 30 (4
deg C)
Day 1
Day 30 (4
deg C)

Viscosity
(cPs)
Particle
Size (nm)
Effect of
Preservat
ive
(Benzalk
onium
Chloride)

PDI

AmB
content
(%)
Viscosity
(cPs)

Day 1
Day 7 (4
deg C)
Day 1
Day 7 (4
deg C)
Day 1
Day 7 (4
deg C)

PEG2K-NLCAmB

PEG2K-NLCAmB Chitosan

PEG2K-NLCAmB Gel

0.05%
0.30%
Very slight
precipitation
observed with 0.3
% drug load only,
easily
redispersible. No
precipitate in the
0.05% formulation

0.30%
Extremely small
amount of
precipitation
observed for 2
months.
Precipitation is
significantly
lower than 0.3%
PEG-NLC-AmB.
Precipitation was
easily
redispersible

0.30%
No
precipitation
observed for 2
months

375 ± 2.91

190 ± 6.2

389.6 ± 0.41

194 ±2.4

0.35 ± 0.009

0.25 ± 0.01

0.41 ± 0.006

0.27 ± 0.005

105.15 ± 3.09

99.15 ± 1.2

100 ±
1.29
105 ±
2.27
0.09 ±
0.02
0.11 ±
0.06
112 ±
3.5

102 ± 0.15

98.6 ± 0.19

NA

7.92

194.3

NA

302 ±
4.56
308 ±
6.45
0.27 ±
0.01
0.3 ±
0.06
95.16 ±
2.5
93.6 ±
5

316 ±
8.77
325 ±
15.47
0.35 ±
0.01
0.36 ±
0.06
92.7 ±
2.5
93.7 ±
7

2.95
250 ±
10.5
255 ±
2.4
0.29 ±
0.02
0.30 ±
0.02
110.24
± 2.7
111.14
± 1.3

3.05
220 ±
6.7
212 ±
4.6
0.31 ±
0.03
0.33 ±
0.02
106.67
± 1.2
105.8 ±
0.4

0.39 ± 0.02

NA

NA

NA

276 ± 2.5
287 ± 5.6

0.4 ± 0.03
NA
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0.05%
0.30%
Clear solution

Formulation
formed gel
(Interaction
with chitosan
due to its
positive
charge)

NA

100 ±
1.29
105 ±
2.27
0.12
±.01
0.07 ±
0.03
120 ±
4.5
125 ±
6

FungizoneTM
(D5W)
0.05
%
0.30%
Clear solution

NA

NA

NA

NA

NA

NA

NA
126 ±
1.9
NA

NA
143 ±
0.1
122.9
± 0.6

NA
96 ±
2.5
708 ±
105
0.09 ±
0.02

NA

NA

NA

NA

NA

1025

NA

NA

NA

NA

1
113 ±
2.1
112 ±
1.5

NA

1
115 ±
0.9
116 ±
1.5

NA

NA

NA

NA

NA

NA

*NA – Not determined/not studied

AmBisome®

NA
NA
NA
NA

NA

In vitro fungicidal activity
Microdilution experiments were performed in wild type (WT) Candida albicans SC5314 (ATCC
MYA-2876) and in AmB resistant Candida albicans (ATCC 200955) as per Clinical & Laboratory
Standards Institute (CLSI) protocols. Recovery assay was performed for fungicidal activity at day
7 post preparation (reconstituted formulations were stored at 4oC).

First NLC-AmB

(unPEGylated), PEG-NLC-AmB, AmB pure compound (AmB) and commercially available AmB
formulations, Fungizone and AmBisome, were tested. The initial studies were performed in the
Ca SC5314 strain in which, PEG-NLC-AmB showed the strongest antifungal activity among
AmB, Fungizone and AmBisome (Fig. 20 A & Table 22). The recovery assay also established
lowest minimum fungicidal concentration (MFC) value for PEG-NLC-AmB i.e. 0.16 µg/mL in
comparison to AmB (1.25 µg/mL), Fungizone (0.31 µg/mL) and AmBisome 1.25 µg/mL). (Fig.
20 A & Table 22). In AmB resistant Candida strain, PEG-NLC-AmB showed similar MIC/MFC
values like Fungizone, but significantly better than AmB and AmBisome (Fig. 20 B & Table 22).
Along with PEG-NLC-AmB formulations, chitosan coated PEG-NLC-AmB formulations as well
as the PEG-NLC-AmB formulations in the in-situ gel system were also tested in both WT and
AmB resistant Candida strains. In Ca SC5314, PEG-NLC-AmB formulations exhibited superior
activity, even after 7 days post reconstitution, compared to the control or the marketed
formulations. Chitosan coating or addition of the gel components did not affect the MIC or MFC.
Moreover, the MIC and MFC of the PEG-NLC-AmB formulations were not affected by the
preservative, BAC, whereas the efficacy of AmBisome and Fungizone were affected (Fig 20A &
Table 22). Although, in AmB resistant Candida strain, coated PEG-NLC-AmB loses its activity
in comparision with PEG-NLC-AmB alone and FunDex-BAC. The placebo formulations, PEGNLC, PEG-NLC-gel or PEG-NLC-Chi, did not exhibit any activity.
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Figure 20: Antifungal activity of AmB formulations. Left panel shows Java Tree
visualization of microdilution assay data. Right panel shows cell recovery on drug-free agar
plates. Each formulation was tested at 10.0- 0.01μg/ml with 2-fold dilutions. Color bar
represents relative growth. A. Antifungal activity on Day 7 post AmB formulation in WT
Candida (SC5314). B. Antifungal activity on Day 7 post AmB formulation in AmB resistant
Candida strain. Each experiment was performed in triplicates.
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Table 22: Summary of Antifungal profile of formulations.

Candida albicans (SC5314)

AmB-resistant Candida albicans

(ATCC MYA-2876)

(ATCC 200955)
MIC/MFC (µg/mL)

Formulations
PEG-NLC-AmB

0.16 / 0.16

1.25 / 1.25

PEG-NLC-AmB-Gel

0.08 / 0.16

2.5 / 2.5

PEG-NLC-AmB-Chi

0.16 / 0.16

5.0 / 10.0

FunDex

0.31 / 0.31

1.25 / 1.25

AmBisome

0.63 / 1.25

NA / NA

PEG-NLC-AmB-BAC

0.08 / 0.16

2.5 / 2.5

PEG-NLC-AmB-Chi-BAC

0.16 / 0.16

5.0 / 10.0

FunDex-BAC

0.31 / 0.63

0.63 / 0.63

AmBisome-BAC

0.63 / 0.63

10 / NA

AmB

1.25 / 1.25

2.5 / 5.0

PEG-NLC

NA / NA

NA / NA

PEG-NLC-Gel

NA / NA

NA / NA

PEG-NLC-Chi

NA / NA

NA / NA

Precorneal tear kinetics
Precorneal tear kinetics provides analysis of concentration available to absorb from precorneal tear
fluid and cul-de-sac. We receive various parameters from precorneal kinetics: t1/2, Cmax, AUC,
MRT. High t1/2 and MRT signifies higher precorneal residence. A formulation that has higher
precorneal residence means amphotericin B can permeate for prolonged period of time. AUC
provides concentration overall in contact with cornea during total time duration. Higher the AUC,
higher concentration gradient across cornea and sclera and possible higher permeation. Precorneal
tear concentrations were determined (Table 24) and plotted against time in Figure 21. Further,
non-compartmental analysis on tear fluid kinetics was applied and summarized in Table 23. From
the precorneal tear fluid kinetics (t1/2) it was evident that PEG2K-NLC-AmB-Gel had ~4-fold
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higher precorneal residence in comparison to AmBisome® (marketed Amphotericin B liposome)
and ~17 fold higher than FungizoneTM. It is also evident that nanoparticles enhance precorneal
residence in comparison to solution (FungizoneTM v/s rest). AUC for amphotericin B formulations
from highest to lowest are: PEG2K-NLC-AmB-Gel>Chi-PEG2K-NLC-AmB> PEG2K-NLCAmB>AmBisome>Fungizone. Therefore, we can conclude that nanoparticles entrapped gel
provided highest great amphotericin B concentration in precorneal region for prolonged duration.
Cmax was consistent with all formulation except in situ gelling system, which had 1.5 higher Cmax,
which signifies lower initial loss upon blinking post administration of dose. Upon administration
of eye drops, we see loss due to overflowing of cul-de-sac. This is not seen in case of nanoparticles
entrapped in in situ gelling system as the eye drop is immediately converted to gel (high viscosity),
and form depot in the cul-de-sac. Similar observation can be made by comparing concentration of
these formulation at time 0 (Table 24).
Table 23: Precorneal tear fluid kinetics.
Parameter

Unit

FungizoneTM

AmBisome®

PEG2KNLC-AmB

t1/2
Cmax/ C0
AUC 0-t
AUC 0inf_obs
AUMC 0inf_obs
MRT 0inf_obs

h
μg/μl
μg/μl*h
μg/μl*h

1.54
4.74
0.85
0.88

4.77
5.36
0.76
0.81

μg/μl*h^2

0.38

h

0.43

2.26
4.90
1.19
1.24

Chitosan
PEG2KNLC-AmB
4.51
5.68
1.27
1.46

PEG2KNLC-AmB
Gel
17.66
7.84
2.05
2.75

0.84

0.94

3.16

22.96

1.04

0.76

2.17

8.35

Overall, PEG2K-NLC-AmB-Gel had higher t1/2, MRT, Cmax, and AUC. Therefore, this
formulation can help us reduce number of dosing required in a day by prolonging amphotericin B
residence in precorneal region.
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Table 24: Summary of concentration at various time point in tear fluid.
Ti
me
(h)
0
0.2
5
0.5
1
2
4

Avg. Conc. (ug/ul)

6

AmBisome
Avg. Conc.
(ug/ul)
SD
3.0
5.36
2
0.0
0.10
3
0.0
0.02
1
0.0
0.01
02
0.0
0.01
04
0.0
0.01
07
0.0
0.08
03

Fungizone
Avg. Conc.
(ug/ul)
SD
1.1
4.74
90
0.0
0.39
54
0.1
0.22
37
0.0
0.05
33
0.0
0.02
17
0.0
0.01
03
0.0
<0.001
00

PEG-NLC
Avg. Conc.
(ug/ul)
SD
1.9
4.89
45
0.3
1.45
61
0.1
0.23
09
0.0
0.01
03
0.0
0.05
11
0.0
0.02
06
0.0
0.01
00

Chitosan PEGNLC
Avg. Conc. S
(ug/ul)
D
1.
5.68
07
0.
1.16
14
0.
0.14
04
0.
0.04
01
0.
0.05
01
0.
0.04
01
0.
0.03
01

PEG-NLC GEL
Avg. Conc.
(ug/ul)
SD
1.3
7.84
32
0.7
2.12
27
0.1
0.41
27
0.1
0.32
08
0.0
0.03
16
0.0
0.04
04
0.0
0.03
07

10.000
9.000
8.000
7.000
6.000
5.000
4.000
3.000
2.000
1.000
0.000
0

AmBisome

0.25

Fungizone

0.5

1
Time (h)

PEG-NLC

Chitosan PEG-NLC

Figure 21: Precorneal amphotericin B tear concentration.
In vivo ocular distribution
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2

4

6

PEG-NLC GEL

This study was performed in total 24 New Zealand albino rabbits. They were divided in 6 groups
with 4 rabbits in each group. Aim of this study was to study amphotericin B biodistribution postdosing of amphotericin B formulations. In previous study (Chapter II) we dosed animals every
hour for 7 hours and sacrificed at 8th hour. This was planned to mimic closely to the regimen
followed in a clinical set-up to treat a patient with fungal infection. We observed that amphotericin
B concentration were statistically equivalent for all the formulations. Since, we modified
formulation for better precorneal residence, to evaluate formulations, dosing was reduced to every
2 hours for 6 hours and sacrifice at 8th hour. This would give idea if formulations survive despite
of number of doses reduced to half. In 2 groups labelled as Chi-PEG2K-NLC-AmB 3and PEG2KNLC-AmB-Gel 3 (Figure 22) formulations were administered every 3 hours (total 3 doses) and
animals were sacrificed at 9th hour. Results are summarized in Figure 22. Results suggest that
PEG2K-NLC-AmB had lowest ocular biodistribution. This relates to its precorneal residence time,
therefore, on reduced dosing formulation failed. In this study concentration in Sclera and Cornea
are key as in state of infection cornea and scleral would have disrupted tight junctions and hence,
permeability would be higher and concentration in ICB, AH, VH would not represent true value.
Corneal concentration of chitosan coated PEGylated amphotericin B loaded nanostructured lipid
carriers was high because of mucoadhesive nature of chitosan. Also, comparing ratio of
concentration in sclera to cornea for formulations, it signifies that amphotericin B permeated
through corneal pathway from chi-PEG2K-NLC-AmB, whereas, amphotericin B from
AmBisome® and PEG2K-NLC-AmB permeate through scleral pathway.
Concentration of amphotericin B from PEG2K-NLC-AmB-Gel were significantly higher and from
precorneal kinetics it is proved that gel retains greater portion of its formulation in precorneal
region. Therefore, number of doses for PEG2K-NLC-AmB-Gel can be reduced without
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compromising effectiveness. More accurate idea on this can be obtained by testing these
formulations on in vivo ocular fungal infection model in future.
0.6

0.4
0.3
0.2
0.1
0.0

Concentration (ug/mL)

0.5

Cornea

ICB

AH

VH

Sclera

Chitosan PEG2K-NLC-AmB 3 PEG2K-NLC-AmB Gel 3
PEG2K-NLC-AmB

Chitosan PEG2K-NLC-AmB

PEG2K-NLC-AmB Gel

AmBisome®

Figure 22: Ocular biodistribution of amphotericin B from amphotericin B loaded PEGylated
(2K) NLC, chitosan coated PEGylated (2K) NLC, and PEGylated (2K) NLC entrapped in
ion sensitive gels in comparison with AmBisome® (marketed preparation—freeze-dried
liposome), in vivo in Albino New Zealand rabbits (Instillation volume 50 µL, Dose 150ug).
The error bars represent standard error. Dosing regimen for PEG2K-NLC-AmB, chitosan
PEG2K-NLC-AmB, and PEG2K-NLC-AmB Gel is 150 ug every 2 hours for 6 hours and
sacrifice rabbits at 8th hour. Whereas, dosing regimen for chitosan PEG2K-NLC-AmB 3,
and PEG2K-NLC-AmB Gel 3 is 150 ug every 3 hours for 6 hours and sacrifice rabbits at 9th
hour.
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Conclusion
Chitosan coated PEG2K-NLC-AmB and PEG2K-NLC-AmB entrapped in gel were formulated. It
was observed that both formulations positively impacted stability. PEG2K-NLC-AmB-Gel
demonstrated significantly prolonged precorneal residence of amphotericin B. Permeation of
amphotericin B from the PEG2K-NLC-AmB-Gel, Chi-PEG2K-NLC-AmB, and PEG2K-NLCAmB formulations were significantly higher in compariosn to AmBisome® (marketed
preparation). PEG2K-NLC-AmB-Gel and Chi-PEG2K-NLC-AmB formulations were able to
maintain statistically indifferent amphotericin B concentration even when number of doses were
further reduced from 8 to 4 to 3. Where, highest amphotericin B formulation, amongst all studied
formulation (except marketed AmBisome®), was in PEG2K-NLC-AmB-Gel. This signifies that
PEG2K-NLC-AmB-Gel formulation prevented loss of amphotericin B while maintaining
concentration of amphotericin B in precorneal region and various ocular tissues. A more complete
idea on performance of these formulations can be gained by testing them on in vivo animal model.
Therefore, from current studies we conclude that we were able to formulate an autoclavable high
amphotericin B loaded stable formulation for ocular drug delivery with—its permeation at par
with marketed preparation, prolonged precorneal residense, stablitiy in presence of preservative,
multidose regimen compatible, significantly enhacned antifungal activity against wildtype and
resistant fungal species, and its permeation at par with AmBisome® (marketed preparation).
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optimization, characterization of drug delivery methadologies as well as \textit{in vivo}
pharmacokinetics, and applied statistics.
Team player: Capable of diligently handling multiple projects, as a part of team as well as
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abstract screener for AAPS conference; reviewer for NIH CORE-NPN mock study section
committee at University of Mississippi; attended and presented multiple posters at Annual
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142

EDUCATION
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Doctor of Philosophy in Pharmaceutics
Graduate Minor in Interdisciplinary Applied Statistics 2015 – 2019


Formulation, optimization of lipid nanoparticles, surface-modified lipid nanoparticles,
and lipid nanoparticles entrapped in gels;
 To study its effect on ex vivo drug permeation and in vivo (rabbits) ocular distribution;
To determine precorneal tear fluid kinetics.
 Study efficacy of various novel formulations of anti-glaucoma drugs for its intraocular
pressure reducing effect in both normotensive
 and glaucoma induced animal model.
 Process as well as formulation optimization using Design of Experiment/ Quality-Based
Design approach.
 Fabrication and optimization of surface engineered lipid nanoparticles for liver targeting
via oral drug delivery route.
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research findings, in vitro, ex vivo, and in vivo.
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Engineered novel surface-modified gold nanoparticles and polymeric micellar systems
for cancer targeting.
Nanoparticle in vitro cellular uptake studies.
Pharmacokinetic modelling of drug in rodents using compartment and non-compartment
modelling.



Worked on the project, Pharmacokinetic evaluation of different sub-lingual DRL
formulations in animal model and first in human dose prediction – using PK Modelling.
Duties included coordinating with CRO to obtain pharmacokinetic data, analyze data
using WinNonLin to obtain pharmacokinetic parameters and provide inference.
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Preformulation: Determination of Solubility, Polymorphism, Stability, Drug-Excipient
and Excipient-Excipient Interaction, Drug degradation kinetics
Engineering and Formulation: Nanotechnology, Drug delivery, Nanoparticle synthesis
(Metal Nanoparticles, Polymeric Nanoparticles, Lipid Nanoparticles, Nanocrystals),
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extrusion, Extruder spheronizer granulator,Wet and dry granulation, Powder
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pharmacokinetic study in small vertebrate animals, performing pharmacokinetic (PK)
modelling to obtain PK parameters. Experience also includes ex vivo drug metabolism
studies using CYP enzymes.
Analytical techniques: Analytical Method and Bio-Analytical Method Development and
validation using HPLC and LC-MS/MS, Dynamic Light Scatteing (DLS), Texture
Analyzer, FTIR, Differential Scanning Calorimetry, Thermogravimetric Analysis,
UV/Vis, Fluorescence Spectrophotometry; Inferring PXRD.
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(Design of Experiments) and modelling data. Expertise in applying various statistical
methods: General Linear Models, Multivariate Models, Mediation & Moderation,
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regression; Logistic Regression; Linear-Mixed Effect Models; parametric and nonparametric tests; chi-square tests; Analysis of Variance and Covariance; Mediation &
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Variance, Repeated-Measures Analysis, Structure Equation Modeling, Path Analysis,
Mediation-Moderation, and Panel data analysis.
Cell Culture: One-year experience working with mammalian Cell Cultures, Cell uptake
Studies, Cell Freezing/Thawing, Fluorescence/Phase Microscopy, ELISA, Western Blots.
Software: Chembiodraw Ultra, Graphpad Prism, Origin pro, JMP, R, SPSS, LaTeX,
Stata.
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